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A B S T R A C T
Background
Fluid excess may place patients undergoing surgery at risk for various complications. Hypertonic saline (HS) maintains intravascular
volume with less intravenous fluid than isotonic salt (IS) solutions, but may increase serum sodium.
Objectives
To determine the benefits and harms of HS versus IS solutions administered to patients undergoing surgery.
Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), (The Cochrane Library) Issue 1, 2009; MEDLINE (1966
to 2009); EMBASE (1980 to 2009); LILACS (to August 2009) and CINAHL (1982 to 2009) without language restrictions.
Selection criteria
We included randomized clinical trials where HS was compared to IS in patients undergoing surgery, irrespective of blinding, language,
and publication status.
Data collection and analysis
We assessed the impact of HS administration on mortality, organ failure, fluid balance, serum sodium, serum osmolarity, diuresis and
physiologic measures of cardiovascular function. We pooled data using odds ratio or mean difference (MD) for binary and continuous
outcomes, respectively, using random-effects models.
Main results
We included 15 studies with 614 participants. One death in each group and no other serious adverse events were reported. While all
patients were in a positive fluid balance postoperatively, the excess was significantly less in HS patients (standardized mean difference
(SMD) -1.43L, 95% confidence interval (CI) 0.8 to 2.1 L less; P < 0.00001). Patients treated with HS received significantly less fluid
than IS-treated patients (MD -2.4L 95% (CI) 1.5 to 3.2 L less; P < 0.00001) without differences in diuresis between the groups.
Maximum intraoperative cardiac index was significantly increased with HS (SMD 0.6 L/min/M2 higher, 95% CI 0.1 to 1.0, P = 0.02)
but Intraoperative pulmonary artery wedge pressure remained unchanged. While the maximum serum sodium and the serum sodium
at the end of the study were significantly higher in HS patients, the level remained within normal limits (136 to 146 meq/L).
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Authors’ conclusions
HS reduces the volume of intravenous fluid required to maintain patients undergoing surgery but transiently increases serum sodium.
It is not known if HS effects patient survival and morbidity but it should be tested in randomized clinical trials that are designed and
powered to test these outcomes.
P L A I N L A N G U A G E S U M M A R Y
Hypertonic saline for peri-operative fluid management
Patients usually require intravenous fluids during surgery. Sometimes large volumes of fluid are given during operations in order to
maintain adequate blood pressure, but these volumes may leave patients with an excessive fluid load in the post-operative period.
Hypertonic saline has a higher sodium concentration than isotonic solutions which have concentrations similar to the blood stream.
Hypertonic saline might benefit patients undergoing surgery by reducing the total volume of fluid required. This review includes 15
trials comparing hypertonic saline to isotonic saline in patients undergoing surgery. These trials suggests that less fluid is required for
maintenance of arterial blood pressure and blood volume in these patients during surgery if hypertonic saline is given. Kidney function
was good in both groups but the serum sodium was higher in patients given hypertonic saline. The trials were too small to see important
differences in patient survival or organ failure.
B A C K G R O U N D
Low volume resuscitation with hypertonic crystalloid solutions
has been investigated for over 20 years (Shackford 1983). More
recently, alterations in cellular immune function with hypertonic
saline (HS) administration have been demonstrated in experimen-
tal and clinical studies (Kolsen-Petersen 2004; Rizoli 2006). Sev-
eral randomized clinical trials (RCTs) of HS resuscitation in criti-
cally ill patients have been performed. A systematic review of HS
compared to isotonic solution in resuscitation following burns or
trauma was unable to reach a conclusion regarding benefit or harm
in the presence of wide confidence intervals (Bunn 2004). Tri-
als of HS alone, or in combination with colloids, have also been
performed in the trauma population. A meta-analysis comparing
250 ml of HS (with or without dextran) with administration of
250 ml of isotonic crystalloid for the treatment of hypotension
either in the field or at admission to the emergency department in
1233 trauma patients failed to demonstrate that HS with dextran
confers a survival benefit (Wade 1997).
Standard perioperative care includes isotonic salt (IS) solution
administration to counter conditions which may cause transient
intra-operative hypovolaemia including: fluid deprivation dur-
ing preoperative fasting; vasodilatation due to epidural or general
anaesthesia; third space sequestration of intravascular fluid; insen-
sible fluid loss and intraoperative fluid or blood loss. These condi-
tions are often reversed at the end of an operation. In fact, IS solu-
tion has been shown to increase the weight of patients undergoing
elective major surgery by an average of three to six kilograms (kg)
(Grocott 2005). While most patients tolerate the additional fluid
well, postoperative improvement or reversal of the conditions out-
lined above may place patients with compromised cardiovascular
or renal function at increased risk for development of pulmonary
oedema. Patients without cardiovascular or renal risk factors may
also be adversely affected by perioperative fluid gain. A recent
RCT demonstrated that perioperative fluid restriction resulted in
fewer major or minor postoperative complications compared to
traditional care in 172 adult patients undergoing elective colorec-
tal surgery (Brandstrup 2003). Another study demonstrated that
fluid overload delayed return of gastrointestinal function (Lobo
2002). Conversely, failure to maintain intravascular volume dur-
ing surgery may place patients at risk for cardiac or cerebral is-
chaemia. Indeed supplemental perioperative fluid administration
has been shown to improve tissue oxygenation (Arkilic 2003).
HS has the potential to reduce the total volume of fluid admin-
istered during operative procedures by allowing patients to draw
fluid from the interstitium (and other body compartments) to
counter perioperative hypotensive effects and thereby provide In-
travascular support without excess fluid administration. In situa-
tions where large volume resuscitation may be harmful, such as in
brain trauma, a role for HS is emerging (Ogden 2005). Notwith-
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standing, several risks have been associated with HS including the
potential hypernatraemia, metabolic acidosis and vasodilatation.
Several RCTs of prophylactic HS administration in the perioper-
ative period have been published. In contrast to other trials where
HS has been combined with colloid solutions to treat hypoten-
sion, these RCTs may provide a clinical picture of the effect of HS
on perioperative fluid management.
O B J E C T I V E S
To determine the benefits and harms of HS versus IS solutions
administered to patients undergoing surgery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs comparing the administration of HS versus
IS solution during operative procedures, regardless of language or
publication status.
Types of participants
We included patients undergoing any surgical procedures.
Types of interventions
We included perioperative administration of either HS or IS so-
lutions. We permitted concomitant measures so long as they ap-
plied to both arms of the study. We excluded studies that com-
pared HS and a colloidal solution to IS alone. Additionally, we
excluded studies that compared HS and IS solutions administered
by inhalation or absorption from the nasal mucosa and involving
nonsurgical patient populations (burns, trauma and head injury).
Types of outcome measures
Primary outcomes
1. Mortality
2. Organ failure. Organ failure was recorded if it was so defined by
each trial or if any of the following occurred: any requirement for
dialysis (renal failure) or prolonged ventilation (pulmonary fail-
ure); use of medical therapy for either pulmonary oedema or circu-
latory support (cardiac failure) or for confusion (cerebral failure).
Secondary outcomes
3. Fluid balance over the study period.We used authors definitions
where provided. For studies not clearly specifying the study period,
we defined it to include the immediate preoperative (induction of
anaesthesia), intraoperative and postoperative periods (up to 24
hours after surgery). For studies that only reported weight change,
we applied a conversion factor, wherein 1 kg = 1 L, to calculate
fluid balance.
4. Total volume of intravenous fluid
5. Perioperative diuresis
6. Maximum serum sodium concentration in the perioperative
period
7. Final serum sodium
8. Duration of endotracheal intubation after operation
9. Duration of stay in intensive care after operation
10. Duration of stay in hospital after operation
11. We recorded any reported serious adverse events such as my-
ocardial infarction, cerebrovascular accidents or central pontine
myelinolysis.
Other outcomes
12. We collected data regarding actual fluid balance, serum osmo-
larity and perioperative haemodynamic parameters if they were
reported by individual trials.
Search methods for identification of studies
Electronic searches
We searched the current issue of the Cochrane Central Register
of Controlled Trials (CENTRAL), (The Cochrane Library Issue 1,
2009); MEDLINE (1966 to August 2009); EMBASE (1980 to
2009 week 18); CINAHL (1982 to August 2009 week 1) and
LILACS (to August 2009) for RCTs comparing hypertonic and
balanced salt solution administration in the perioperative period.
We originally used the search strategy described in the appen-
dices (Appendix 1 MEDLINE; Appendix 2 EMBASE; Appendix
3 CINAHL; Appendix 4 LILACS; Appendix 5 CENTRAL) to
search until April 2007. We updated this search to August 2009
(see Appendix 6).
We limited the publication types to clinical trials, controlled clin-
ical trials, RCTs, multi-centre studies and meta-analyses.
In addition we searched trial registries including http://
clinicaltrials.gov/, http://www.controlled-trials.com/ and http://
www.ifpma.org/clinicaltrials.html for ongoing trials. We sought
letter or email contact with principal investigators to inform them
of the meta-analysis and to ask for additional information.
We did not apply any language restrictions.
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Searching other resources
We hand searched the bibliographies of retrieved articles and the
abstracts of conference proceedings published in Anaesthesia and
Intensive Care; Anaesthesia and Analgesia; British Journal of Surgery;
Critical Care Medicine; Journal of Vascular Surgery and Trauma;
Injury; and Infection and Critical Care for the years 2000 to 2006.
Data collection and analysis
Trial identification
Vivian McAlister (VM) scanned titles and abstracts identified by
the initial search to exclude overlapped and irrelevant studies. Two
authors (Tammy Znajda (TZ) and Karen Burns (KB)) identified
trials that met our inclusion criteria. Brian Church (BC) resolved
differences in data recorded and all differences of opinion were
otherwise resolved through discussion.
Data abstraction
Data were abstracted independently by at least two of the authors
from the studies using standardized forms developed for this re-
view. We wrote to primary study authors for information regard-
ing missing data or data that was not clearly stated. We resolved
differences of opinion through discussion. We abstracted data per-
taining to the included participants, interventions applied and
outcomes reported for each trial using a standardized form.
We abstracted the following details from each of the included
studies:
1. patients (inclusion and exclusion criteria; mean age;
proportion of men; aetiology of disease; weight before and after
surgery; serum electrolytes before, during and after surgery);
2. interventions (type of surgery; concentration and volume of
hypertonic saline given; total volume of fluid administered and
concomitant therapy);
3. trials (setting; methodological quality; publication status;
duration of follow-up and all outcomes).
If standard error of themeanwas recorded in a study, we converted
it to standard deviation.
Methodological quality
We followed the guidelines of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2008).We used Review
Manager Version 5.0(RevMan 5.0). We assessed factors related to
applicability of findings, validity of individual studies, and certain
design characteristics that affect interpretation of results, including
double-blinding and adherence to the intention-to-treat principle.
We evaluated the included studies for selection, performance, at-
trition and detection bias. All three authors independently assessed
the methodological quality of the included studies including the
generation of allocation sequence (evaluated adequate (if the allo-
cation sequence was generated by a computer or random number
table), unclear (if the trial was described as randomized, but the
method used for the allocation sequence generation was not de-
scribed) or inadequate (if a system involving dates, names, or ad-
mittance numbers were used)), allocation concealment (evaluated
as A (adequate), B (unclear), C (inadequate) or D (not used)) and
adherence to the intention-to-treat principle. We resolved differ-
ences of opinion through discussion until consensus was achieved.
Analysis
We assessed statistical heterogeneity using the I 2 statistic (Higgins
2002). We used a random-effects model anticipating between
study, as well as within study, heterogeneity (DerSimonian 1986).
We performed subgroup analyses where appropriate. We summa-
rized dichotomous and continuous outcomes using the odds ratio
(OR) and mean difference (using the inverse variance method),
respectively.We calculated an overall standardizedmean difference
(SMD).
We performed subgroup analysis, where appropriate, by calcula-
tion of an OR or SMD in each subgroup and examination of the
95% confidence intervals (CI). A lack of overlap between two CI
in the subgroup analyses was interpreted to represent a statisti-
cally significant difference. We conducted all analyses using the
intention-to-treat principle where possible. If analysis based on
this principle was not possible, we stated this clearly.
Sensitivity analyses
Weperformed sensitivity analyses for missing data and study qual-
ity.
Missing data: We employed sensitivity analyses using different
approaches for imputing missing data. For the best-case scenario
we assumed that none of the originally enrolled patients missing
from the primary analysis in the treatment group developed the
negative outcome of interest, whilst all those missing from the
control group did. For the worst-case scenario we assumed the
converse.
Study quality: We performed analysis based on the presence or
absence of a reliable random allocation method, concealment of
allocation and blinding of participants or outcome assessors.
Subgroup analysis
When appropriate after consideration of statistical and clinical
heterogeneity, we performed subgroup analyses based on:
1. operation type
2. dose of HS (trials were stratified into three comparisons
according to the dose of HS which was calculated as the volume
of 3% HS required to give the same amount of sodium: 7 ml/kg
or less (comparison 01); 7.1 - 10 ml/kg (comparison 02); > 10
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ml/kg (comparison 03). These dose stratifications were chosen
before the review was conducted on the basis of an anticipated
range of HS doses)
3. volume of crystalloid given to the control group (trials were
stratified into three comparisons according to the total volume of
fluid transfusion received by IS patients: < 2 L (comparison 01); 2
L to 5 L (comparison 02); > 5 L (comparison 03). These volume
stratifications were chosen in advance of the review on the basis
of an anticipated range of peri-operative fluid administration)
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
From 215 potential reports identified by the initial search strategy,
18 reports met the criteria for further assessment (Figure 1). Of
these 18 references, we excluded three studies after detailed review
because they were not randomized (Auler 1987; Shao 2005) or
did not report any of the outcomes of interest (Auler 1992) (see
Characteristics of excluded studies). No ongoing or recently com-
pleted studieswere identified in registries of clinical trials including
http://clinicaltrials.gov/; http://www.controlled-trials.com/; and
http://www.ifpma.org/clinicaltrials.html.
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Figure 1. Searching results
Fifteen studies including 614 participants met our inclusion cri-
teria (Baraka 1994; Bruegger 2005; Cross 1989; Durasnel 1999;
Ishikawa 1996; Jarvela 2000; Jarvela 2001; Kato 1996; Kimura
1994; Kolsen-Petersen 2004; Shackford 1983; Shackford 1987;
Veroli 1992; Wang 1997; Younes 1988) (see Characteristics of
included studies). The included trials were performed in a wide
variety of surgical situations: aortic surgery (four trials) (Bruegger
2005; Shackford 1983; Shackford 1987; Younes 1988); lower limb
surgery (three trials) (Ishikawa 1996; Jarvela 2000; Veroli 1992);
transurethral prostate resection (three trials) (Baraka 1994; Kato
1996; Kimura 1994); coronary artery bypass grafting (two tri-
als) (Cross 1989; Jarvela 2001); hysterectomy (one trial) (Kolsen-
Petersen 2004); hernia repair (one trial) (Wang 1997); general
surgery (one trial) (Durasnel 1999). Anaesthetic techniques in-
cluded: general anaesthesia (eight trials) (Bruegger 2005; Cross
1989; Jarvela 2001; Kato 1996; Kolsen-Petersen 2004; Shackford
1983; Shackford 1987; Younes 1988) and spinal anaesthesia (seven
trials) (Baraka 1994; Durasnel 1999; Ishikawa 1996; Jarvela 2000;
Kimura 1994; Veroli 1992; Wang 1997).
Studies were performed in nine countries. Four publications were
written in languages other than English including Japanese (two
trials) (Ishikawa 1996; Kimura 1994); French (one trial) (Durasnel
1999); Portuguese (one trial) (Younes 1988). The included stud-
ies had small sample sizes, enrolling between 20 and 72 patients.
The interval between the first and last study was approximately
22 years (1983 to 2005). None of the studies were designed to
determine differences in mortality but instead focused on fluid
and haemodynamicmeasurement during the perioperative period.
Follow-up extended into the postoperative period in eight trials
(Bruegger 2005; Cross 1989; Jarvela 2000; Jarvela 2001; Kato
1996; Kolsen-Petersen 2004; Shackford 1983; Shackford 1987)
for durations ranging from the stay in the recovery unit to the hos-
pital stay while the other trials confined their observations to the
period of anaesthesia. Two studies reported results with standard
error which were converted to standard deviation by multiplica-
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tion with the square root of the number in the group (Shackford
1983; Shackford 1987).
Risk of bias in included studies
Randomization
Randomization procedures were described in all but four trials (
Ishikawa 1996; Kimura 1994; Wang 1997; Younes 1988). Ade-
quate allocation concealment was reported in one trial (Kolsen-
Petersen 2004). We verified the adequacy of allocation conceal-
ment in two further trials (Jarvela 2000; Jarvela 2001) through
correspondence with the principal investigator. We could not re-
liably assess allocation concealment from the published reports of
the remaining studies.
Participant baseline characteristics
Baseline parameters were reported in each study and appeared to
be similar in both study groups in all trials.
Blinding
All studies blinded therapy to participants and investigators.
Compliance with protocol
Of the 614 enrolled participants, 607 completed the proto-
col. Three participants in the HS group failed to complete the
study, one because of consent withdrawal (Kolsen-Petersen 2004);
one for an anaphylactic reaction to another medication (Kolsen-
Petersen 2004); and one without a reason specified (Durasnel
1999). Three participants in the IS group failed to complete the
protocol, one because of an urgent return to the operating room
for control of haemorrhage (Kolsen-Petersen 2004); one because
of a transfer to another hospital (Kolsen-Petersen 2004) and one
without a reason specified (Durasnel 1999). One enrolled patient
failed to complete the protocol but neither the reason nor the
group were specified (Ishikawa 1996).
Intention-to-treat analysis
No patients who completed the protocol were lost to follow up
and intention-to-treat analysis was used in all studies.
Effects of interventions
Primary outcomes
1. Mortality
All trials were presumed to have reported all deaths because other
outcomes such as serum sodium were reported at the end of the
study period. Only two deaths were reported by the included trials
for an overall survival rate of 99.7%. Both deaths occurred in one
trial, one in each group (Shackford 1983).
2. Organ failure
No episodes of organ failure were reported by any of the included
trials.
Secondary outcomes
3. Fluid balance
(Analysis 3.1; Analysis 3.2; Analysis 3.3; Analysis 3.4; Analysis
3.5)
Perioperative fluid balance was calculated in five trials with 230
participants (Bruegger 2005; Cross 1989; Jarvela 2001; Shackford
1983; Shackford 1987). Overall, the fluid balance was positive in
both groups but this positive balance was significantly less with
HS administration than with IS administration (SMD -1.43L,
95% confidence interval (CI) 0.8 to 2.1 L less; P < 0.00001; I2
= 76%). Subgroup analysis suggested no significant effect of the
type of surgery (Analysis 3.1), dose of HS given (Analysis 3.2),
the total volume of fluid transfused (Analysis 3.3) or study quality
(Analysis 3.4). Actual fluid balance (Analysis 3.5) was reported
by four trials with 158 participants (Bruegger 2005; Cross 1989;
Shackford 1983; Shackford 1987). The positive fluid balance was
significantly less in the HS group compared to the IS group (SMD
-1.63L, 95% CI 0.9 to 2.3L less; P < 0.00001; I2 = 69%), a result
almost identical to the calculated balance.
4. Intravenous fluid volume administered
(Analysis 4.1; Analysis 4.2; Analysis 4.3)
The volume of intravenous fluid administered to patients was re-
ported in six trials with 270 patients (Bruegger 2005; Cross 1989;
Jarvela 2001; Shackford 1983; Shackford 1987) Patients in the
HS group received considerably less fluid intravenously than pa-
tients in the IS groups (SMD -2.4L 95% (CI) 1.5 to 3.2 less; P
< 0.00001; I2 = 90%). The high degree of heterogeneity for this
outcome was not explained by subgroup analysis according to type
of surgery (Analysis 4.1) or the dose of HS (Analysis 4.2). Funnel
plot analysis showed this outcome to cluster symmetrically (Figure
2) except for two outliers from studies (Shackford 1983, Shackford
1987) that used considerably more HS than other trials. However,
exclusion of these two trials from the analysis did not eliminate
heterogeneity. Total fluid transfusion in IS groups exceeded that
in HS groups for each subgroup analysed. Sensitivity analysis by
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study quality (Analysis 4.3) did not alter the outcome. No hetero-
geneity was seen in the two studies where quality was graded as A
but it was present in the other groups.
Figure 2. Funnel plot of comparison: 4 Total volume of crystalloid administered (L), outcome: 4.3 Volume
of crystalloid administered (sensitivity analysis by study quality).
5. Perioperative diuresis
(Analysis 5.1; Analysis 5.2; Analysis 5.3; Analysis 5.4; Analysis
5.5)
Urine output during the trial was reported in six trials including
270participants (Bruegger 2005;Cross 1989; Jarvela 2000; Jarvela
2001; Shackford 1983; Shackford 1987). There was no difference
in perioperative urine output between the two groups;( Analysis
5.1 SMD +0.2 L, (95% CI -0.2 to +0.6), P = 0.78, I2 = 68%).
Stratification by type of surgery (Analysis 5.1) or dose of HS (
Analysis 5.2) did not affect the degree of heterogeneity. However
heterogeneity was eliminated when the trials were stratified by
the total volume of crystalloid use in the IS group (Analysis 5.4).
Sensitivity analysis by study quality (Analysis 5.5) did not change
the outcome or the heterogeneity of the studies.
6. Maximum serum sodium
(Analysis 6.1; Analysis 6.2; Analysis 6.3; Analysis 6.4)
The maximum serum sodium was measured in all of the trials
except one (Durasnel 1999), and included 532 participants. Max-
imum serum sodium was higher in the HS group than the IS
group (SMD +2.24 meq/L more with HS, 95% CI 1.6 to 2.9,
P < 0.00001, I2 = 88%). The maximum serum sodium ranged
between 136 and 159 in HS groups compared to between 137
and 143 meq/L in the IS groups. The maximum serum sodium
was higher with HS in each subgroup. Subgroup analysis by type
of surgery (Analysis 6.1) or by volume of crystalloid administered
(Analysis 6.3) did not alter the outcome or the heterogeneity be-
tween trials. Stratification of subgroups by dose of HS (Analysis
6.2) showed the increase in peak serum sodium with HS to be
related to the dose of HS administered (MD +3.6 meq/L, 95%
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CI 2.6 to 4.8 where the dose equivalent of 3% HS was 7 ml/kg
or less compared to MD +9.98 meq/L, 95% CI 6.1 to 13.9 where
dose was > 7 ml 3% HS/kg). Funnel plot analysis which showed
peak serum sodium of each study to cluster symmetrically around
a positiveMD in theHS group illustrates the relationship between
dose of HS and increase in peak sodium (Figure 3). Sensitivity
analysis by study quality did not change the outcome or the het-
erogeneity of the studies (Analysis 6.4).
Figure 3. Funnel plot of comparison: 6 Peak serum sodium (meq/L), outcome: 6.2 Peak serum sodium
(stratified by dose of HS).
7. Final serum sodium
(Analysis 7.1; Analysis 7.2; Analysis 7.3; Analysis 7.4; Analysis
7.5)
By the end of the study period the difference between the groups
in serum sodium was considerably reduced (SMD 1.07 meq/L
higher with HS, 95% CI 0.6 to 1.5, P < 0.00001, I2 = 90%)
and the range for average final serum sodium was within normal
limits: 136 to 146 meq/L and 136 to 140 in the HS and IS groups
respectively (Analysis 7.1).Neither the outcome nor heterogeneity
were altered in subgroup analysis by surgery type (Analysis 7.4),
dose of HS (Analysis 7.2) or volume of crystalloid (Analysis 7.3).
Funnel plot analysis is similar to that observed with peak serum
sodium except that the difference between HS and IS has been
reduced (Figure 4).
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Figure 4. Funnel plot of comparison: 7 Final serum sodium (meq/L), outcome: 7.2 Final serum sodium
(stratified by dose of HS given).
8-10. Duration of endotracheal intubation, intensive care
stay and hospital stay
The duration of mechanical ventilation and the length of stay in
hospital were not reported in any of the trials. Only one trial (
Cross 1989) reported the length of stay in intensive care withmean
stays (standard deviation) of 2.3 (0.2) versus 2.4 (0.6) days in the
HS ans IS groups respectively (P = 0.63).
11. Adverse events
No serious adverse events such as myocardial infarction, cere-
brovascular accident or central pontine myelinolysis were reported
in these trials.
12. Serum osmolarity, haemodynamic parameters
(Analysis 12.1; Analysis 12.2; Analysis 12.3)
Trials in which maximum serum osmolarity (Analysis 12.1) was
measured (Ishikawa 1996; Jarvela 2000; Jarvela 2001; Kato 1996;
Kimura 1994; Kolsen-Petersen 2004; Shackford 1983; Shackford
1987; Younes 1988) showed an increase with HS that was similar
to the increase in serum sodium (SMD2.7mOsm/ kgH2Ohigher
with HS, 95% CI 1.7 to 3.7, P < 0.00001, I2 = 90%). Several
groups measured haemodynamic parameters (Cross 1989; Jarvela
2000; Jarvela 2001; Shackford 1983; Shackford 1987). Maximum
intraoperative cardiac index (Analysis 12.3) was significantly in-
creased with HS (SMD 0.6 L/min/M2 higher with HS, 95% CI
0.1 to 1.0, P = 0.02, I2 = 59%) but intraoperative pulmonary
artery wedge pressure (Analysis 12.2) remained unchanged by HS
(SMD 0, 95% CI -0.3 to +0.3, P = 0.98, I2 = 0).
D I S C U S S I O N
There were no differences with respect to mortality or major mor-
bidity between the treatment arms of this meta-analysis. A pre-
liminary survey carried out before designing this meta-analysis
suggested that trials of perioperative HS were usually designed to
measure fluid volumes, haemodynamics and biochemistry rather
than measure important clinical outcomes. Despite this, we chose
mortality as the primary outcome for this review and we collected
serious adverse event data because of their clinical importance. As
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expected, we found no trials that were designed to measure dif-
ferences in mortality or serious adverse events and in general the
study periods of the included trials were insufficient to determine
the impact of the interventions on mortality. Only one death and
no organ failures were reported in 297 patients who received HS,
just as in the IS group. Neither the trials nor the meta-analysis
are sufficiently powered to determine the impact of HS on peri-
operative mortality or morbidity. The low mortality rate in the
IS group suggests that normal risk patients were studied and in
which adequate power would require many times the number of
patients collected in this meta-analysis. However the absence of
excess mortality ormorbidity in theHS group despite a wide range
of doses administered suggests that HS is safe. Therefore an alter-
native strategy for consideration is to study perioperative HS in a
population at higher risk of death or major morbidity.
Meta-analysis of the outcomes measured by the trials was per-
formed on less clinically relevant outcomes in order to provide a
picture of the impact of HS on perioperative fluid management.
HS significantly reduces the positive fluid balance experienced by
patients undergoing surgery. This observation was independent of
the type of surgery or perioperative fluid protocol. HS conserved
fluid at lower doses as much as at higher doses.
The principal barrier to meta-analysis of some outcomes is a high
degree of heterogeneity between the trials. Heterogeneity appears
to be due to differences in the magnitude of the effect observed
rather than differences in the effect itself. Subgroup analysis identi-
fied sources of heterogeneity in some instances. For example, con-
siderable heterogeneity was observed in perioperative diuresis even
though there was no significant difference in diuresis between the
test group, HS, and the control. Stratification by the volume of in-
travenous fluid eliminated heterogeneity. Thismakes clinical sense
in that diuresis is directly related to the volume of fluid infused.
It also highlights the variability in the fluid regimen used in these
trials. While such variability increases the clinical applicability of
the review, it also contributes to heterogeneity of the observations.
Other potential sources of heterogeneity such as concommitant
medications were not amenable to investigation because of lack of
information.
Perioperative diuresiswas similar in theHS and IS patients suggest-
ing that adequate intravascular volumes weremaintained through-
out surgery despite the fact that HS patients received significantly
less intravenous fluid than IS patients. HS increased the intraop-
erative cardiac index. All of the patient groups completed surgery
with a positive fluid balance. In some trials, the positive fluid bal-
ance was almost 10 L by the end of surgery. Pulmonary oedema
was not recorded in the trials but it is reasonable to be concerned
that excess fluid of this magnitude would result in pulmonary
oedema in a population at risk of this complication. Use of HS
significantly reduced the positive fluid balance experienced by all
patients undergoing surgery. HS increased serum sodium and os-
molarity in a dose related manner. The doses of HS varied con-
siderably between trials, but even in those who received very high
doses of HS, no adverse events related to hypernatraemia were
encountered. Serum sodium returned to normal limits by the end
of the study.
Is there a potential therapeutic window for HS in patients under-
going surgery, where perioperative weight gain can be minimized
without a risk of significant hypernatraemia?In hyponatraemic pa-
tients, the risk of central pontine myelinolysis is thought to be
related to underlying conditions more than the rate of electrolyte
repletion but increases in serum sodium of more than 10 meq/L
per day should be avoided if possible (Kumar 2006). It is not
known if patients with normal serum sodium are at a similar risk
of hyperosmotically induced demyelination. No episodes of cen-
tral pontine myelinolysis were reported in these studies where the
patients had normal serum sodium levels at baseline and we did
not find any case reports in the literature of central pontine myeli-
nolysis in patients who received HS. Hypernatraemia is transient
after administration of HS. However, it would seem prudent to
avoid large increases in serum sodium. This is possible, with these
studies suggesting that up to 10 ml/kg of 3% HS will reduce the
positive fluid balance perioperatively by up to 1.5 L in the average
adult without increasing serum sodium inappropriately. There is
insufficient evidence to determine if such a reduction in perioper-
ative fluid excess would improve clinically relevant outcomes but
it provides the basis for an RCT.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Small volumes of HS reduced the positive fluid balance and tran-
siently increased serum sodium in patients undergoing surgery.
The impact of HS on clinically relevant outcomes was not tested
by the trials analysed and we cannot recommend routine periop-
erative use of HS across the surgical population. HS may be useful
when fluid restriction is required in selected individuals or clinical
situations.
Implications for research
HS administration to patients undergoing surgery should be com-
pared to standard practice using RCTs of high methodological
rigour in order to determine any impact on patient survival and
other clinically relevant outcomes. Sample size estimation is prob-
lematic given the very low reported incidence of mortality or sig-
nificant morbidity in the control group in these trials. The dura-
tion of any future trial should be sufficient to cover the period of
perioperative mortality or major morbidity which is usually con-
sidered to be 60 days or at least the postoperative hospital stay.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Baraka 1994
Methods Publication type: full article
Allocation random: yes
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: yes
Additional features to blind fluid administered: no
Control of co-interventions: yes
Completeness of follow-up: yes
Intention-to-treat analysis: yes
Participants Country: Lebanon
Language: English
Single centre
Inclusion criteria: consenting adult male patients undergoing transurethral resection of the prostate under
spinal anaesthesia
Exclusion criteria: ASA IV
Number eligible: not specified
Number enrolled: 33 (HS 17; NS 16)
Number completed study: 33
Interventions Hypertonic saline group
IV solution: 3% HS
Dose: 7 ml / kg
Duration: before spinal anaesthesia
Isotonic salt solution group
IV solution: NS
Dose: 7 ml / kg
Duration: before spinal anaesthesia
Co-interventions:
Co-interventions applied differentially between groups: no
Study Period: duration of surgery
Outcomes Mortality
Peak serum sodium
Haemodynamic parameters
Notes
Risk of bias
Item Authors’ judgement Description
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Baraka 1994 (Continued)
Allocation concealment? Unclear B - Unclear
Bruegger 2005
Methods Publication type: full article
Allocation random: yes
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: no
Additional features to blind fluid administered: no
Control of co-interventions: no
Completeness of follow-up: yes
Intention-to-treat analysis: yes
Participants Country: Germany
Language: English
Single centre
Inclusion criteria: patients undergoing elective infrarenal aortic aneurysm repair
Exclusion criteria: ASA IV; renal dysfunction; congestive heart failure; recent brain infarction; contra-
indication to starch or dextran
Number eligible: Not specified
Number enrolled: 28 (HS 14; NS 14)
Number completed study: 28
Interventions Hypertonic saline group
IV solution: 7.5% NaCl
Dose: 250 ml
Isotonic salt solution group
IV solution: NS
Dose: 250 ml
Co-interventions: dextran 70 given with HS; hydroxyethyl starch given with NS
Co-interventions applied differentially between groups: yes
Study Period: duration of surgery plus 72 hours
Outcomes Mortality
Fluid volume transfused
Blood transfused
Fluid loss
Fluid balance
Peak serum sodium
Urine output
Haemodynamic parameters
Notes Different colloids given to experimental and control groups
Risk of bias
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Bruegger 2005 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Cross 1989
Methods Publication type: full article
Allocation random: yes
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: yes
Additional features to blind fluid administered: no
Control of co-interventions: yes
Completeness of follow-up: yes
Intention-to-treat analysis: yes
Participants Country: USA
Language: English
Inclusion criteria: consenting patients undergoing coronary artery bypass
Exclusion criteria: cardiac arrhythmia; cardiac, pulmonary, renal, hepatic failure
Number eligible: not given
Number enrolled: 20 (HS 11; ISS 9)
Number completed study: 20
Interventions Hypertonic saline group
IV solution: HS (1.8%, 304 meq Na/L)
Dose: 100 cc/hour
Duration: Postoperative admission to ICU for 24 hours
Subsequent maintenance: D5/0.45NaCl if serum sodium > 155 meq/L
Isotonic salt solution group
IV solution: NS
Dose: 100 cc/hour
Duration: admission to ICU for 24 hours
Post-operative maintenance: D5/0.45NaCl if serum sodium > 155 meq/L
Co-interventions:
Co-interventions applied differentially between groups: no
Study Period: 24 hours from the beginning of surgery
Outcomes Mortality
LOS hospital
LOS ICU
Fluid volume transfused
Blood transfused
Fluid loss
Fluid balance
Peak serum sodium
Urine output
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Cross 1989 (Continued)
Haemodynamic parameters
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Durasnel 1999
Methods Publication type: full article
Allocation random: yes
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: yes
Additional features to blind fluid administered: no
Control of co-interventions: yes
Completeness of follow-up: yes
Intention-to-treat analysis: yes
Participants Country: Niger
Language: French
Single centre
Inclusion criteria: consenting adult patients undergoing surgery using spinal anaesthesia
Exclusion criteria: systemic infection, coagulopathy, allergy to local anaesthetic, uncorrected hypovolaemia,
congestive heart failure, kidney failure
Number eligible: not specified
Number enrolled: 50 (HS 25; ISS 25)
Number completed study: 48 (one from each group excluded, cause not given)
Interventions Hypertonic saline group
IV solution: 7.5% HS
Dose: 100 ml
Duration: prior to anaesthesia
Isotonic salt solution group
IV solution: 0.9% NaCl
Dose: 100 ml
Duration: prior to anaesthesia
Co-interventions:
Co-interventions applied differentially between groups: no
Study Period: duration of surgery
Outcomes Mortality
Haemodynamic parameters
Fluid volume transfused
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Durasnel 1999 (Continued)
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Ishikawa 1996
Methods Publication type: full article
Allocation random: unclear
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: no
Additional features to blind fluid administered: no
Control of co-interventions: yes
Completeness of follow-up: no (one patient in RL group excluded during study)
Intention-to-treat analysis: yes
Participants Country: Japan
Language: Japanese
Inclusion criteria: Patients undergoing lower limb or pelvic surgery with epidural anaesthesia
Exclusion criteria: ASA classification II, III or IV; MAP decrease by 50 mm Hg
Number eligible: 24
Number enrolled: 24
Number completed study: 23
Interventions Hypertonic saline group
IV solution: 7.2% HS
Dose: 1.8 ml / kg
Duration: 20 minute
Post-operative maintenance: ISS
Isotonic salt solution group
IV solution: NS
Dose: 1 - 2 ml / kg / hr
Duration: study period
Co-interventions: epidural anaesthesia
Co-interventions applied differentially between groups: no
Study Period: duration of surgery
Outcomes Peak serum sodium
Haemodynamic parameters
Notes Translations supplied by Dr Hideaki Tanaka and Dr Yoshihisa Morita
Risk of bias
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Ishikawa 1996 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Jarvela 2000
Methods Publication type: full article
Allocation random: yes
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: yes
Additional features to blind fluid administered: no
Control of co-interventions: yes
Completeness of follow-up: yes
Intention-to-treat analysis: yes
Participants Country: Finland
Language: English
Single centre
Inclusion criteria: consenting fit patients have lower limb surgery under spinal anaesthesia
Exclusion criteria: ASA III or IV
Number eligible: not specified
Number enrolled: 40 (HS 20; ISS 20)
Number completed study: 40
Interventions Hypertonic saline group
IV solution: 7.5% HS
Dose: 4 ml/kg
Duration: 30 minute
Post-operative maintenance: D5 / 0.3% NaCl at 1 ml/kg/hour
Isotonic salt solution group
IV solution: NS
Dose: 4 ml/kg
Duration: 30 minute
Post-operative maintenance: D5 / 0.3% NaCl at 1 ml/kg/hour
Co-interventions:
Co-interventions applied differentially between groups: no
Study Period: duration of surgery and post-anaesthetic recovery period
Outcomes Mortality
Fluid volume transfused
Fluid loss
Fluid balance
Peak serum sodium
Urine output
Haemodynamic parameters
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Jarvela 2000 (Continued)
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Jarvela 2001
Methods Publication type: full article Allocation random: yes Allocation concealment: not described Baseline com-
parison: yes Baseline similarity: yes Blinding of care givers: no Additional features to blind fluid adminis-
tered: no Control of co-interventions: yes Completeness of follow-up: yes Intention-to-treat analysis: yes
Participants Country: Finland
Language: English
Single centre
Inclusion criteria: Patients undergoing elective coronary artery bypass graft
Exclusion criteria: not specified
Number eligible: not specified
Number enrolled: 72 (HS 36; ISS 36)
Number completed study: 72
Interventions Hypertonic saline group
IV solution: 7.5% HS
Dose: 4 ml/kg
Duration: 30 minute
Post-operative maintenance: D5 / 0.3% NaCl at 1 ml/kg/hour
Isotonic salt solution group
IV solution: NS
Dose: 4 ml/kg
Duration: 30 minute
Post-operative maintenance: D5 / 0.3% NaCl at 1 ml/kg/hour
Co-interventions: 4% albumin to maintain cardiac index at 2.5 L / min / m2
Co-interventions applied differentially between groups: no
Study Period: duration of surgery and post-operative period until next morning
Outcomes Mortality
Fluid volume transfused
Weight gain
Fluid loss
Fluid balance
Peak serum sodium
Urine output
Haemodynamic parameters
Extubation times
Notes
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Jarvela 2001 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Kato 1996
Methods Publication type: full article
Allocation random: yes
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: yes
Additional features to blind fluid administered: no
Control of co-interventions: yes
Completeness of follow-up: yes
Intention-to-treat analysis: yes
Participants Country: Japan
Language: English
Inclusion criteria: consenting patients undergoing transurethral resection of the prostate
Exclusion criteria: not given
Number eligible: not given
Number enrolled: 40 (HS 20; ISS 20)
Number completed study: 40
Interventions Hypertonic saline group
IV solution: 3% HS
Dose: 4 ml/kg/min
Duration: adjusted to maintain mean arterial pressure at 80% of preoperative value
Isotonic salt solution group
IV solution: RL
Dose: 4 ml/kg/min
Duration: adjusted to maintain mean arterial pressure at 80% of preoperative value
Post-operative maintenance:
Co-interventions:
Co-interventions applied differentially between groups: no
Study Period: duration of surgery plus first post-operative day.
Outcomes Mortality
Fluid volume transfused
Peak serum sodium
Haemodynamic parameters
Notes
Risk of bias
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Kato 1996 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Kimura 1994
Methods Publication type: full article
Allocation random: unclear
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: unclear
Additional features to blind fluid administered: no
Control of co-interventions: yes
Completeness of follow-up: yes
Intention-to-treat analysis: unclear
Participants Country: Japan
Language: Japanese
Inclusion criteria: patients undergoing transurethral resection of the prostate, spinal anaesthesia
Exclusion criteria: ASA III, IV; hypertension; diabetes; endocrine disease.
Number eligible: 14
Number enrolled: 14 (HS 7; ISS 7)
Number completed study: 14
Interventions Hypertonic saline group
IV solution: HS (213 meq Na / L)
Dose: 8 ml / kg / hour for 1st hour; 4 ml / kg / hour for 2nd hour; 2 ml / kg / hour for 3rd hour.
Isotonic salt solution group
IV solution: RL
Dose: 8 ml / kg / hour for 1st hour; 4 ml / kg / hour for 2nd hour; 2 ml / kg / hour for 3rd hour.
Co-interventions: spinal anaesthesia
Co-interventions applied differentially between groups: no
Study Period: duration of surgery
Outcomes Peak serum sodium
Haemodynamic parameters
plasma aldosterone, ADH
Notes Translation provided by Dr Hideaki Tanaka and Dr Yoshihisa Morita
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Kolsen-Petersen 2004
Methods Publication type: full article
Allocation random: yes
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: no
Additional features to blind fluid administered: no
Control of co-interventions: yes
Completeness of follow-up: yes
Intention-to-treat analysis: yes
Participants Country: Denmark
Language: English
Inclusion criteria: adult female patients undergoing elective hysterectomy
Exclusion criteria: ASA III or IV; cardiac failure; renal failure; anaemia; diabetes mellitus; certain medica-
tions that effect the immune response
Number eligible: 192 screened
Number enrolled: 62 (HS 21; NS-4 21; NS-32 20)
Number completed study: 58 (one HS patient withdrew consent; one HS had anaphylactoid reaction to
anaesthetic agent; one NS-4 patient transferred to another hospital; one NS-32 patient returned to the
operating room for haemorrhage)
Interventions Hypertonic saline group
IV solution: 7.5% NaCl
Dose: 4 ml / kg
Duration: over 10 minutes before hysterectomy
Post-operative maintenance: not specified
Isotonic salt solution group
IV solution: NS
Dose - two groups: ’NS-4’ received 4 ml / kg; ’NS-32’ received 32 ml / kg
Duration: over 10 minutes before hysterectomy
Post-operative maintenance: not specified
Co-interventions: anaesthesia, analgesia
Co-interventions applied differentially between groups: no
Study Period: duration of surgery plus 48 hours after closure of the wound.
Outcomes Mortality
Peak serum sodium
Urine output
Immunological parameters
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
24Hypertonic saline for peri-operative fluid management (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Shackford 1983
Methods Publication type: full article
Allocation random: yes
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: no
Additional features to blind fluid administered: no
Control of co-interventions: yes
Completeness of follow-up: yes
Intention-to-treat analysis: yes
Participants Country: USA
Language: English
Inclusion criteria: patients undergoing aortic surgery
Exclusion criteria: not specified
Number eligible: 61
Number enrolled: 58 (HS 30; ISS 28)
Number completed study: 58
Interventions Hypertonic saline group
IV solution: HSL (250 meq Na/L)
Dose: titrated to maintain CVP within 3 torr of preoperative value
Duration: during operation
Post-operative maintenance: D5/0.25NaCl
Isotonic salt solution group
IV solution: RL
Dose: titrated to maintain CVP within 3 torr of preoperative value
Duration: during operation
Post-operative maintenance: D5/0.25NaCl
Co-interventions:
Co-interventions applied differentially between groups: no
Study Period: duration of hospital stay for surgery
Outcomes Mortality
Fluid volume transfused
Blood transfused
Fluid loss
Fluid balance
Peak serum sodium
Urine output
Haemodynamic parameters
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
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Shackford 1987
Methods Publication type: full article
Allocation random: yes
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: no
Additional features to blind fluid administered: no
Control of co-interventions: yes
Completeness of follow-up: yes
Intention-to-treat analysis: yes
Participants Country: USA
Language: English
Inclusion criteria: Patients undergoing aortic aneurysm repair or aorto-bifemoral bypass
Exclusion criteria: not specified
Number eligible: 52
Number enrolled: 52 (HS 26; ISS 26)
Number completed study: 52
Interventions Hypertonic saline group
IV solution: HSL (250 meq Na/L)
Dose: titrated to maintain CVP within 3 torr of preoperative value
Duration: during operation
Post-operative maintenance: D5/0.25NaCl
Isotonic salt solution group
IV solution: RL
Dose: titrated to maintain CVP within 3 torr of preoperative value
Duration: during operation
Post-operative maintenance: D5/0.25NaCl
Co-interventions:
Co-interventions applied differentially between groups: no
Study Period: duration of surgery plus first four post-operative days
Outcomes Fluid volume transfused
Blood transfused
Fluid loss
Fluid balance
Weight change
Peak serum sodium
Urine output
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Veroli 1992
Methods Publication type: full article
Allocation random: yes
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: yes
Additional features to blind fluid administered: yes (second anaesthetist)
Control of co-interventions: yes
Completeness of follow-up: yes
Intention-to-treat analysis: yes
Participants Country: France
Language: English
Inclusion criteria: consenting patients having lower limb surgery with lumbar extradural anaesthesia
Exclusion criteria: not specified
Number eligible: not specified
Number enrolled: 30 (HS 10; RL 10; NS 10)
Number completed study: 30
Interventions Hypertonic saline group
IV solution: HS 5%
Dose: 2.3 ml.kg
Duration: preoperative bolus
Isotonic salt solution group
IV solution: RL or NS
Dose: 15 ml RL / kg or 13 ml NS / kg
Duration: preoperative bolus
Co-interventions:
Co-interventions applied differentially between groups: no
Study Period: duration of surgery
Outcomes Mortality
Fluid volume transfused
Fluid loss
Fluid balance
Peak serum sodium
Urine output
Haemodynamic parameters
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Wang 1997
Methods Publication type: full article
Allocation random: unclear
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: unclear
Additional features to blind fluid administered: no
Control of co-interventions: yes
Completeness of follow-up: yes
Intention-to-treat analysis: yes
Participants Country: China
Language: English
Single centre
Inclusion criteria: consenting fit patients having herniorrhaphy under spinal anaesthesia
Exclusion criteria: ASA II, III or IV
Number eligible: not specified
Number enrolled: 60 (HS 30; ISS 30)
Number completed study: 60
Interventions Hypertonic saline group
IV solution: 3% HS
Dose: 7 ml / kg
Duration: bolus before surgery
Isotonic salt solution group
IV solution: 0.9% NaCl
Dose: 7 ml / kg
Duration: bolus before surgery
Co-interventions:
Co-interventions applied differentially between groups: no
Study Period: duration of surgery
Outcomes Hypotension
Peak serum sodium
Haemodynamic parameters
Notes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Younes 1988
Methods Publication type: full article
Allocation random: unclear
Allocation concealment: not described
Baseline comparison: yes
Baseline similarity: yes
Blinding of care givers: unclear
Additional features to blind fluid administered: no
Control of co-interventions: yes
Completeness of follow-up: yes
Intention-to-treat analysis: yes
Participants Country: Brazil
Language: Portuguese
Single centre
Inclusion criteria: Adult patients undergoing aortic aneurysm repair or aortobifemoral bypass
Exclusion criteria: not given
Number eligible: not given
Number enrolled: 31 (HS 18; ISS 13)
Number completed study: 31
Interventions Hypertonic saline group
IV solution: 7.5% HS
Dose: 4 ml / kg
Duration: 15 minute bolus
Post-operative maintenance: ISS to maintain CVP and MAP within 10% of starting value
Isotonic salt solution group
IV solution: 0.9% NaCl
Dose: 4 ml / kg
Duration: 15 minute bolus
Post-operative maintenance: ISS to maintain CVP and MAP within 10% of starting value
Co-interventions:
Co-interventions applied differentially between groups: no
Study Period: duration of surgery
Outcomes Mortality
LOS hospital
LOS ICU
Fluid volume transfused
Blood transfused
Fluid loss
Fluid balance
Peak serum sodium
Urine output
Haemodynamic parameters
Notes Translation provided by Ms. Christiane Baldwin
Risk of bias
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Younes 1988 (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
ASA: American Society Anesthesiology classification
HS: hypertonic saline
HSL: hypertonic saline lactate
NS: normal saline (154 meq Na per litre)
RL: Ringer’s Lactate (130 meq Na per litre)
HSL: hypertonic sodium lactate
D5/0.45NS: dextrose 5% in 0.45% saline
ISS: isotonic salt solution
IV: intravenous
LOS: length of stay
ICU: intensive care unit
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Characteristics of excluded studies [ordered by study ID]
Auler 1987 Consecutive patients enrolled. Study not randomized
Auler 1992 Study of intraoperative respiratory physiology but did not measure outcomes such as weight gain, fluid balance or peak
serum sodium or determine postoperative survival.
Shao 2005 Dr Shao kindly responded to an email query on November 30, 2006: “I performed this project non-randomly, allocated
distinct groups on the basis of different diseases and operation methods, but single-blinded (for patients)”.
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D A T A A N D A N A L Y S E S
Comparison 3. Fluid balance (L)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Calculated fluid balance
(stratified for surgery type)
5 230 Std. Mean Difference (IV, Random, 95% CI) -1.43 [-2.05, -0.80]
1.1 Coronary artery bypass
surgery
2 92 Std. Mean Difference (IV, Random, 95% CI) -1.51 [-3.17, 0.15]
1.2 Aortic surgery 3 138 Std. Mean Difference (IV, Random, 95% CI) -1.46 [-2.21, -0.72]
2 Calculated fluid balance
(stratified for dose of HS given)
5 230 Std. Mean Difference (IV, Random, 95% CI) -1.42 [-2.05, -0.79]
2.1 < 7.1 mL 3% HS/kg 0 0 Std. Mean Difference (IV, Random, 95% CI) Not estimable
2.2 7.1 - 10 mL 3% HS/kg 2 100 Std. Mean Difference (IV, Random, 95% CI) -0.82 [-1.23, -0.41]
2.3 > 10 mL 3% HS/kg 3 130 Std. Mean Difference (IV, Random, 95% CI) -1.84 [-2.72, -0.97]
3 Calculated fluid balance
(stratified for volume given in
control group)
5 230 Std. Mean Difference (IV, Random, 95% CI) -1.42 [-2.05, -0.79]
3.1 < 2000 mL 0 0 Std. Mean Difference (IV, Random, 95% CI) Not estimable
3.2 2000 - 5000 mL 3 120 Std. Mean Difference (IV, Random, 95% CI) -1.24 [-2.07, -0.42]
3.3 > 5000 mL 2 110 Std. Mean Difference (IV, Random, 95% CI) -1.65 [-2.72, -0.57]
4 Calculated fluid balance
(sensitivity analysis by study
quality)
5 230 Std. Mean Difference (IV, Random, 95% CI) -1.45 [-2.11, -0.79]
4.1 Study grade = A 1 72 Std. Mean Difference (IV, Random, 95% CI) -0.75 [-1.23, -0.27]
4.2 Study group = B 3 100 Std. Mean Difference (IV, Random, 95% CI) -1.37 [-2.07, -0.67]
4.3 Study group = D 1 58 Std. Mean Difference (IV, Random, 95% CI) -2.32 [-1.00, -1.65]
5 Actual fluid balance (L) 4 158 Std. Mean Difference (IV, Random, 95% CI) -1.63 [-2.32, -0.93]
Comparison 4. Total volume of crystalloid administered (L)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Volume of crystalloid
administered (stratified for type
of surgery)
10 364 Std. Mean Difference (IV, Random, 95% CI) -2.35 [-3.21, -1.49]
1.1 Cardiovascular surgery 6 221 Std. Mean Difference (IV, Random, 95% CI) -1.70 [-2.48, -0.93]
1.2 Non cardiovascular
surgery
4 143 Std. Mean Difference (IV, Random, 95% CI) -4.04 [-6.46, -1.62]
2 Volume of crystalloid
administered (stratified by dose
of HS)
10 364 Std. Mean Difference (IV, Random, 95% CI) -2.35 [-3.21, -1.49]
2.1 < 7.1 mL 3% HS/kg 3 103 Std. Mean Difference (IV, Random, 95% CI) -2.24 [-3.93, -0.56]
2.2 7.1 - 10 mL 3% HS/kg 4 131 Std. Mean Difference (IV, Random, 95% CI) -3.49 [-5.72, -1.26]
32Hypertonic saline for peri-operative fluid management (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2.3 > 10 mL 3% HS/kg 3 130 Std. Mean Difference (IV, Random, 95% CI) -1.22 [-1.98, -0.46]
3 Volume of crystalloid
administered (sensitivity
analysis by study quality)
10 364 Std. Mean Difference (IV, Random, 95% CI) -1.70 [-2.29, -1.12]
3.1 Study grade = A 2 72 Std. Mean Difference (IV, Random, 95% CI) -2.83 [-5.40, -0.26]
3.2 Study group = B 7 234 Std. Mean Difference (IV, Random, 95% CI) -1.51 [-2.17, -0.86]
3.3 Study grade = D 1 58 Std. Mean Difference (IV, Random, 95% CI) -1.03 [-1.58, -0.48]
Comparison 5. Diuresis during study period (L)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Diuresis during study period (L) 6 270 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.19, 0.58]
2 Diuresis during study period
(stratified by dose of HS)
6 270 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.23, 0.57]
2.1 < 7.1 mL 3% HS/kg 0 0 Std. Mean Difference (IV, Random, 95% CI) Not estimable
2.2 7.1 - 10 mL 3% HS/kg 3 140 Std. Mean Difference (IV, Random, 95% CI) 0.15 [-0.25, 0.55]
2.3 > 10 mL 3% HS/kg 3 130 Std. Mean Difference (IV, Random, 95% CI) 0.33 [-0.51, 1.17]
3 Diuresis during study period
(stratified for type of surgery)
6 270 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.20, 0.61]
3.1 Cardiovascular surgery 5 230 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.29, 0.70]
3.2 Non cardiovascular
surgery
1 40 Std. Mean Difference (IV, Random, 95% CI) 0.25 [-0.37, 0.87]
4 Diuresis during study period
(stratified for volume of
crystalloid infused)
6 270 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.23, 0.57]
4.1 < 2000 mL 2 68 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.55, 0.40]
4.2 2000 - 5000 mL 2 92 Std. Mean Difference (IV, Random, 95% CI) 0.94 [-0.25, 2.12]
4.3 > 5000 mL 2 110 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.50, 0.25]
5 Diuresis during study period
(sensitivity analysis by study
quality)
6 270 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.23, 0.57]
5.1 Study grade = A 2 112 Std. Mean Difference (IV, Random, 95% CI) 0.29 [-0.08, 0.66]
5.2 Study grade = B 3 100 Std. Mean Difference (IV, Random, 95% CI) 0.33 [-0.64, 1.30]
5.3 Study grade = D 1 58 Std. Mean Difference (IV, Random, 95% CI) -0.16 [-0.67, 0.36]
Comparison 6. Peak serum sodium (meq/L)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Peak serum sodium (stratified by
type of surgery)
14 532 Std. Mean Difference (IV, Random, 95% CI) 2.24 [1.59, 2.89]
1.1 Cardiovascular surgery 6 261 Std. Mean Difference (IV, Random, 95% CI) 3.20 [1.98, 4.42]
1.2 Transurethral resection of
the prostate
3 87 Std. Mean Difference (IV, Random, 95% CI) 1.17 [0.22, 2.11]
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1.3 Other surgery 5 184 Std. Mean Difference (IV, Random, 95% CI) 1.89 [0.97, 2.81]
2 Peak serum sodium (stratified by
dose of HS)
14 532 Std. Mean Difference (IV, Random, 95% CI) 2.24 [1.59, 2.89]
2.1 < 7.1 mL 3% HS/kg 5 178 Std. Mean Difference (IV, Random, 95% CI) 1.11 [0.54, 1.68]
2.2 7.1 - 10 mL 3% HS/kg 5 210 Std. Mean Difference (IV, Random, 95% CI) 3.26 [1.96, 4.57]
2.3 > 10 mL 3% HS/kg 4 144 Std. Mean Difference (IV, Random, 95% CI) 2.43 [1.44, 3.41]
3 Peak serum sodium (stratified by
volume given in control group)
9 371 Std. Mean Difference (IV, Random, 95% CI) 2.69 [1.89, 3.48]
3.1 < 2000 mL/kg 4 141 Std. Mean Difference (IV, Random, 95% CI) 1.76 [1.22, 2.31]
3.2 2000 - 5000 mL 3 120 Std. Mean Difference (IV, Random, 95% CI) 5.06 [3.28, 6.84]
3.3 > 5000 mL 2 110 Std. Mean Difference (IV, Random, 95% CI) 1.91 [1.16, 2.67]
4 Peak serum sodium (sensitivity
analysis by study quality)
14 532 Mean Difference (IV, Random, 95% CI) 7.64 [5.47, 9.80]
4.1 Study grade = A 2 112 Mean Difference (IV, Random, 95% CI) 7.50 [2.60, 12.40]
4.2 Study grade = B 11 362 Mean Difference (IV, Random, 95% CI) 7.33 [4.59, 10.08]
4.3 Study grade = D 1 58 Mean Difference (IV, Random, 95% CI) 12.0 [8.09, 15.91]
Comparison 7. Final serum sodium (meq/L)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Final serum sodium (all studies) 10 392 Std. Mean Difference (IV, Random, 95% CI) 1.07 [0.60, 1.54]
2 Final serum sodium (stratified
by dose of HS given)
10 392 Std. Mean Difference (IV, Random, 95% CI) 1.07 [0.60, 1.54]
2.1 < 7.1 mL 3% HS/kg 2 100 Std. Mean Difference (IV, Random, 95% CI) 0.89 [0.47, 1.30]
2.2 7.1 - 10 mL 3% HS/kg 5 162 Std. Mean Difference (IV, Random, 95% CI) 1.07 [0.06, 2.07]
2.3 > 10 mL 3% HS/kg 3 130 Std. Mean Difference (IV, Random, 95% CI) 1.21 [0.43, 2.00]
3 Final serum sodium (stratified by
volume given in control group)
8 293 Std. Mean Difference (IV, Random, 95% CI) 1.17 [0.55, 1.79]
3.1 < 2000 mL 3 111 Std. Mean Difference (IV, Random, 95% CI) 0.96 [-0.49, 2.42]
3.2 2000 - 5000 mL 3 72 Std. Mean Difference (IV, Random, 95% CI) 1.73 [0.68, 2.78]
3.3 > 5000 mL 2 110 Std. Mean Difference (IV, Random, 95% CI) 0.83 [0.43, 1.22]
4 Final serum sodium (stratified
by type of surgery)
10 392 Std. Mean Difference (IV, Random, 95% CI) 1.07 [0.60, 1.54]
4.1 Cardiovascular surgery 5 182 Std. Mean Difference (IV, Random, 95% CI) 1.28 [0.65, 1.91]
4.2 Transurethral resection of
prostate
1 40 Std. Mean Difference (IV, Random, 95% CI) 0.78 [0.14, 1.43]
4.3 Other surgery 4 170 Std. Mean Difference (IV, Random, 95% CI) 0.91 [-0.04, 1.87]
5 Final serum sodium (sensitivity
analysis by study quality)
10 392 Mean Difference (IV, Random, 95% CI) 3.18 [1.91, 4.44]
5.1 Study grade = A 2 80 Mean Difference (IV, Random, 95% CI) 3.45 [0.51, 6.39]
5.2 Study grade = B 7 254 Mean Difference (IV, Random, 95% CI) 2.74 [1.11, 4.38]
5.3 Study grade = D 1 58 Mean Difference (IV, Random, 95% CI) 10.0 [3.75, 16.25]
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Comparison 12. Other outcomes of interest
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximum intraoperative serum
osmolarity (mOsm/kg H2O)
9 329 Std. Mean Difference (IV, Random, 95% CI) 2.72 [1.73, 3.71]
2 Maximum intraoperative
pulmonary artery wedge
pressure (mm Hg)
3 150 Std. Mean Difference (IV, Random, 95% CI) -0.00 [-0.33, 0.32]
3 Maximum intraoperative cardiac
index (L/min/M2)
5 210 Std. Mean Difference (IV, Random, 95% CI) 0.55 [0.10, 1.00]
Analysis 3.1. Comparison 3 Fluid balance (L), Outcome 1 Calculated fluid balance (stratified for surgery
type).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 3 Fluid balance (L)
Outcome: 1 Calculated fluid balance (stratified for surgery type)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Coronary artery bypass surgery
Cross 1989 11 -1.72 (0.73) 9 0.27 (0.83) 13.5 % -2.46 [ -3.68, -1.23 ]
Jarvela 2001 36 0.8 (1.5) 36 1.9 (1.4) 23.9 % -0.75 [ -1.23, -0.27 ]
Subtotal (95% CI) 47 45 37.4 % -1.51 [ -3.17, 0.15 ]
Heterogeneity: Tau2 = 1.23; Chi2 = 6.47, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 1.78 (P = 0.076)
2 Aortic surgery
Shackford 1983 30 4.2 (1.6) 28 9.8 (3.2) 21.2 % -2.21 [ -2.87, -1.55 ]
Shackford 1987 26 5.5 (1.5) 26 9.8 (5.1) 22.3 % -1.13 [ -1.72, -0.54 ]
Bruegger 2005 14 3.6 (2) 14 5.31 (1.1) 19.2 % -1.03 [ -1.82, -0.23 ]
Subtotal (95% CI) 70 68 62.6 % -1.46 [ -2.21, -0.72 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 7.26, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 3.85 (P = 0.00012)
Total (95% CI) 117 113 100.0 % -1.43 [ -2.05, -0.80 ]
Heterogeneity: Tau2 = 0.37; Chi2 = 16.42, df = 4 (P = 0.003); I2 =76%
Test for overall effect: Z = 4.46 (P < 0.00001)
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Analysis 3.2. Comparison 3 Fluid balance (L), Outcome 2 Calculated fluid balance (stratified for dose of HS
given).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 3 Fluid balance (L)
Outcome: 2 Calculated fluid balance (stratified for dose of HS given)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 7.1 mL 3% HS/kg
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 7.1 - 10 mL 3% HS/kg
Bruegger 2005 14 3.6 (2.04) 14 5.31 (1.08) 19.2 % -1.02 [ -1.81, -0.22 ]
Jarvela 2001 36 0.8 (1.5) 36 1.9 (1.4) 23.8 % -0.75 [ -1.23, -0.27 ]
Subtotal (95% CI) 50 50 43.0 % -0.82 [ -1.23, -0.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.92 (P = 0.000087)
3 > 10 mL 3% HS/kg
Cross 1989 11 -1.72 (0.73) 9 0.27 (0.83) 13.5 % -2.46 [ -3.68, -1.23 ]
Shackford 1983 30 4.2 (1.6) 28 9.8 (3.2) 21.2 % -2.21 [ -2.87, -1.55 ]
Shackford 1987 26 5.5 (1.5) 26 9.8 (5.2) 22.3 % -1.11 [ -1.69, -0.52 ]
Subtotal (95% CI) 67 63 57.0 % -1.84 [ -2.72, -0.97 ]
Heterogeneity: Tau2 = 0.43; Chi2 = 7.65, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 4.13 (P = 0.000037)
Total (95% CI) 117 113 100.0 % -1.42 [ -2.05, -0.79 ]
Heterogeneity: Tau2 = 0.37; Chi2 = 16.51, df = 4 (P = 0.002); I2 =76%
Test for overall effect: Z = 4.43 (P < 0.00001)
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Analysis 3.3. Comparison 3 Fluid balance (L), Outcome 3 Calculated fluid balance (stratified for volume
given in control group).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 3 Fluid balance (L)
Outcome: 3 Calculated fluid balance (stratified for volume given in control group)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 2000 mL
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 2000 - 5000 mL
Bruegger 2005 14 3.6 (2.04) 14 5.31 (1.08) 19.2 % -1.02 [ -1.81, -0.22 ]
Cross 1989 11 -1.72 (0.73) 9 0.27 (0.83) 13.5 % -2.46 [ -3.68, -1.23 ]
Jarvela 2001 36 0.8 (1.5) 36 1.9 (1.4) 23.8 % -0.75 [ -1.23, -0.27 ]
Subtotal (95% CI) 61 59 56.5 % -1.24 [ -2.07, -0.42 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 6.48, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 2.97 (P = 0.0030)
3 > 5000 mL
Shackford 1983 30 4.2 (1.6) 28 9.8 (3.2) 21.2 % -2.21 [ -2.87, -1.55 ]
Shackford 1987 26 5.5 (1.5) 26 9.8 (5.2) 22.3 % -1.11 [ -1.69, -0.52 ]
Subtotal (95% CI) 56 54 43.5 % -1.65 [ -2.72, -0.57 ]
Heterogeneity: Tau2 = 0.50; Chi2 = 5.95, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 2.99 (P = 0.0028)
Total (95% CI) 117 113 100.0 % -1.42 [ -2.05, -0.79 ]
Heterogeneity: Tau2 = 0.37; Chi2 = 16.51, df = 4 (P = 0.002); I2 =76%
Test for overall effect: Z = 4.43 (P < 0.00001)
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Analysis 3.4. Comparison 3 Fluid balance (L), Outcome 4 Calculated fluid balance (sensitivity analysis by
study quality).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 3 Fluid balance (L)
Outcome: 4 Calculated fluid balance (sensitivity analysis by study quality)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Study grade = A
Jarvela 2001 36 0.8 (1.5) 36 1.9 (1.4) 23.5 % -0.75 [ -1.23, -0.27 ]
Subtotal (95% CI) 36 36 23.5 % -0.75 [ -1.23, -0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0021)
2 Study group = B
Bruegger 2005 14 3.6 (2.04) 14 5.31 (1.08) 19.3 % -1.02 [ -1.81, -0.22 ]
Cross 1989 11 -1.72 (0.73) 9 0.27 (0.83) 14.0 % -2.46 [ -3.68, -1.23 ]
Shackford 1987 26 5.5 (1.5) 26 9.8 (5.2) 22.2 % -1.11 [ -1.69, -0.52 ]
Subtotal (95% CI) 51 49 55.5 % -1.37 [ -2.07, -0.67 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 4.29, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 3.83 (P = 0.00013)
3 Study group = D
Shackford 1983 30 4.2 (1.6) 28 9.8 (3) 21.0 % -2.32 [ -3.00, -1.65 ]
Subtotal (95% CI) 30 28 21.0 % -2.32 [ -3.00, -1.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.73 (P < 0.00001)
Total (95% CI) 117 113 100.0 % -1.45 [ -2.11, -0.79 ]
Heterogeneity: Tau2 = 0.42; Chi2 = 18.12, df = 4 (P = 0.001); I2 =78%
Test for overall effect: Z = 4.30 (P = 0.000017)
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Analysis 3.5. Comparison 3 Fluid balance (L), Outcome 5 Actual fluid balance (L).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 3 Fluid balance (L)
Outcome: 5 Actual fluid balance (L)
Study or subgroup Hypertonic Saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bruegger 2005 14 3.6 (2.03) 14 5.3 (1.08) 25.2 % -1.02 [ -1.81, -0.22 ]
Cross 1989 11 -1.72 (0.73) 9 0.27 (0.83) 17.4 % -2.46 [ -3.68, -1.23 ]
Shackford 1983 30 4.2 (1.6) 28 9.8 (3.2) 27.9 % -2.21 [ -2.87, -1.55 ]
Shackford 1987 26 5.5 (1.5) 26 9.8 (5.2) 29.5 % -1.11 [ -1.69, -0.52 ]
Total (95% CI) 81 77 100.0 % -1.63 [ -2.32, -0.93 ]
Heterogeneity: Tau2 = 0.34; Chi2 = 9.83, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 4.56 (P < 0.00001)
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Analysis 4.1. Comparison 4 Total volume of crystalloid administered (L), Outcome 1 Volume of crystalloid
administered (stratified for type of surgery).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 4 Total volume of crystalloid administered (L)
Outcome: 1 Volume of crystalloid administered (stratified for type of surgery)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiovascular surgery
Bruegger 2005 14 1.92 (0.7) 14 2.72 (0.68) 11.1 % -1.13 [ -1.93, -0.32 ]
Cross 1989 11 4.17 (0.41) 9 5.77 (0.79) 9.8 % -2.52 [ -3.75, -1.28 ]
Jarvela 2001 16 0.55 (0.18) 16 1.44 (0.23) 9.6 % -4.20 [ -5.50, -2.90 ]
Shackford 1983 30 6.4 (4.6) 28 12.5 (6.9) 11.7 % -1.03 [ -1.58, -0.48 ]
Shackford 1987 26 6.3 (2.4) 26 9.5 (5.8) 11.7 % -0.71 [ -1.27, -0.15 ]
Younes 1988 18 0.7 (0.05) 13 0.81 (0.09) 11.1 % -1.54 [ -2.37, -0.72 ]
Subtotal (95% CI) 115 106 65.1 % -1.70 [ -2.48, -0.93 ]
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(. . . Continued)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.74; Chi2 = 28.50, df = 5 (P = 0.00003); I2 =82%
Test for overall effect: Z = 4.29 (P = 0.000018)
2 Non cardiovascular surgery
Durasnel 1999 24 0.39 (0.22) 24 0.62 (0.32) 11.7 % -0.82 [ -1.42, -0.23 ]
Ishikawa 1996 8 0.1 (0.02) 7 0.98 (0.15) 4.0 % -8.04 [ -11.55, -4.54 ]
Jarvela 2000 20 0.13 (0.03) 20 1.03 (0.16) 7.8 % -7.66 [ -9.54, -5.79 ]
Kato 1996 20 0.81 (0.35) 20 1.62 (0.62) 11.4 % -1.58 [ -2.30, -0.86 ]
Subtotal (95% CI) 72 71 34.9 % -4.04 [ -6.46, -1.62 ]
Heterogeneity: Tau2 = 5.22; Chi2 = 59.84, df = 3 (P<0.00001); I2 =95%
Test for overall effect: Z = 3.28 (P = 0.0011)
Total (95% CI) 187 177 100.0 % -2.35 [ -3.21, -1.49 ]
Heterogeneity: Tau2 = 1.56; Chi2 = 89.63, df = 9 (P<0.00001); I2 =90%
Test for overall effect: Z = 5.36 (P < 0.00001)
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Analysis 4.2. Comparison 4 Total volume of crystalloid administered (L), Outcome 2 Volume of crystalloid
administered (stratified by dose of HS).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 4 Total volume of crystalloid administered (L)
Outcome: 2 Volume of crystalloid administered (stratified by dose of HS)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 7.1 mL 3% HS/kg
Durasnel 1999 24 0.39 (0.22) 24 0.62 (0.32) 11.7 % -0.82 [ -1.42, -0.23 ]
Ishikawa 1996 8 0.1 (0.02) 7 0.98 (0.15) 4.0 % -8.04 [ -11.55, -4.54 ]
Kato 1996 20 0.81 (0.35) 20 1.62 (0.62) 11.4 % -1.58 [ -2.30, -0.86 ]
Subtotal (95% CI) 52 51 27.1 % -2.24 [ -3.93, -0.56 ]
Heterogeneity: Tau2 = 1.63; Chi2 = 17.25, df = 2 (P = 0.00018); I2 =88%
Test for overall effect: Z = 2.61 (P = 0.0090)
2 7.1 - 10 mL 3% HS/kg
Bruegger 2005 14 1.92 (0.7) 14 2.72 (0.68) 11.1 % -1.13 [ -1.93, -0.32 ]
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Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Jarvela 2000 20 0.13 (0.03) 20 1.03 (0.16) 7.8 % -7.66 [ -9.54, -5.79 ]
Jarvela 2001 16 0.55 (0.18) 16 1.44 (0.23) 9.6 % -4.20 [ -5.50, -2.90 ]
Younes 1988 18 0.7 (0.05) 13 0.81 (0.09) 11.1 % -1.54 [ -2.37, -0.72 ]
Subtotal (95% CI) 68 63 39.6 % -3.49 [ -5.72, -1.26 ]
Heterogeneity: Tau2 = 4.78; Chi2 = 51.01, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 3.06 (P = 0.0022)
3 > 10 mL 3% HS/kg
Cross 1989 11 4.17 (0.41) 9 5.77 (0.79) 9.8 % -2.52 [ -3.75, -1.28 ]
Shackford 1983 30 6.4 (4.6) 28 12.5 (6.9) 11.7 % -1.03 [ -1.58, -0.48 ]
Shackford 1987 26 6.3 (2.4) 26 9.5 (5.8) 11.7 % -0.71 [ -1.27, -0.15 ]
Subtotal (95% CI) 67 63 33.3 % -1.22 [ -1.98, -0.46 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 6.78, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 3.16 (P = 0.0016)
Total (95% CI) 187 177 100.0 % -2.35 [ -3.21, -1.49 ]
Heterogeneity: Tau2 = 1.56; Chi2 = 89.63, df = 9 (P<0.00001); I2 =90%
Test for overall effect: Z = 5.36 (P < 0.00001)
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Analysis 4.3. Comparison 4 Total volume of crystalloid administered (L), Outcome 3 Volume of crystalloid
administered (sensitivity analysis by study quality).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 4 Total volume of crystalloid administered (L)
Outcome: 3 Volume of crystalloid administered (sensitivity analysis by study quality)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Study grade = A
Jarvela 2000 16 0.55 (0.18) 16 1.44 (0.23) 8.2 % -4.20 [ -5.50, -2.90 ]
Jarvela 2001 20 0.81 (0.35) 20 1.62 (0.62) 11.4 % -1.58 [ -2.30, -0.86 ]
Subtotal (95% CI) 36 36 19.6 % -2.83 [ -5.40, -0.26 ]
Heterogeneity: Tau2 = 3.16; Chi2 = 12.00, df = 1 (P = 0.00053); I2 =92%
Test for overall effect: Z = 2.16 (P = 0.031)
2 Study group = B
Bruegger 2005 14 1.92 (0.7) 14 2.72 (0.68) 10.9 % -1.13 [ -1.93, -0.32 ]
Cross 1989 11 4.17 (0.41) 9 5.77 (0.79) 8.5 % -2.52 [ -3.75, -1.28 ]
Durasnel 1999 24 0.39 (0.22) 24 0.62 (0.32) 12.1 % -0.82 [ -1.42, -0.23 ]
Ishikawa 1996 8 0.1 (0.02) 7 0.98 (0.15) 2.3 % -8.04 [ -11.55, -4.54 ]
Kato 1996 20 0.81 (0.35) 20 1.62 (0.62) 11.4 % -1.58 [ -2.30, -0.86 ]
Shackford 1987 26 6.3 (2.4) 26 9.5 (5.8) 12.2 % -0.71 [ -1.27, -0.15 ]
Younes 1988 18 0.7 (0.05) 13 0.81 (0.09) 10.8 % -1.54 [ -2.37, -0.72 ]
Subtotal (95% CI) 121 113 68.2 % -1.51 [ -2.17, -0.86 ]
Heterogeneity: Tau2 = 0.53; Chi2 = 25.24, df = 6 (P = 0.00031); I2 =76%
Test for overall effect: Z = 4.52 (P < 0.00001)
3 Study grade = D
Shackford 1983 30 6.4 (4.6) 28 12.5 (6.9) 12.3 % -1.03 [ -1.58, -0.48 ]
Subtotal (95% CI) 30 28 12.3 % -1.03 [ -1.58, -0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.68 (P = 0.00023)
Total (95% CI) 187 177 100.0 % -1.70 [ -2.29, -1.12 ]
Heterogeneity: Tau2 = 0.64; Chi2 = 46.38, df = 9 (P<0.00001); I2 =81%
Test for overall effect: Z = 5.73 (P < 0.00001)
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Analysis 5.1. Comparison 5 Diuresis during study period (L), Outcome 1 Diuresis during study period (L).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 5 Diuresis during study period (L)
Outcome: 1 Diuresis during study period (L)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bruegger 2005 14 1.2 (0.55) 14 1.5 (1.33) 14.2 % -0.29 [ -1.03, 0.46 ]
Cross 1989 11 4.5 (0.5) 9 3.8 (0.25) 9.3 % 1.64 [ 0.59, 2.69 ]
Jarvela 2000 20 0.45 (0.28) 20 0.43 (0.27) 17.0 % 0.07 [ -0.55, 0.69 ]
Jarvela 2001 36 3.35 (1.04) 36 2.94 (0.85) 21.0 % 0.43 [ -0.04, 0.89 ]
Shackford 1983 30 1.8 (0.8) 28 1.8 (1.6) 19.7 % 0.0 [ -0.52, 0.52 ]
Shackford 1987 26 0.7 (0.7) 26 1.1 (5.8) 18.9 % -0.10 [ -0.64, 0.45 ]
Total (95% CI) 137 133 100.0 % 0.20 [ -0.19, 0.58 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 11.61, df = 5 (P = 0.04); I2 =57%
Test for overall effect: Z = 1.00 (P = 0.32)
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Analysis 5.2. Comparison 5 Diuresis during study period (L), Outcome 2 Diuresis during study period
(stratified by dose of HS).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 5 Diuresis during study period (L)
Outcome: 2 Diuresis during study period (stratified by dose of HS)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 7.1 mL 3% HS/kg
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 7.1 - 10 mL 3% HS/kg
Bruegger 2005 14 1.2 (0.55) 14 1.5 (1.33) 14.4 % -0.29 [ -1.03, 0.46 ]
Jarvela 2000 20 0.45 (0.28) 20 0.43 (0.27) 17.0 % 0.07 [ -0.55, 0.69 ]
Jarvela 2001 36 3.35 (1.04) 36 2.94 (0.85) 20.6 % 0.43 [ -0.04, 0.89 ]
Subtotal (95% CI) 70 70 52.1 % 0.15 [ -0.25, 0.55 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 2.69, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 0.75 (P = 0.45)
3 > 10 mL 3% HS/kg
Cross 1989 11 4.5 (0.5) 9 3.8 (0.25) 9.7 % 1.64 [ 0.59, 2.69 ]
Shackford 1983 30 1.6 (0.8) 28 1.8 (1.6) 19.5 % -0.16 [ -0.67, 0.36 ]
Shackford 1987 26 0.7 (0.7) 26 1.1 (5.8) 18.8 % -0.10 [ -0.64, 0.45 ]
Subtotal (95% CI) 67 63 47.9 % 0.33 [ -0.51, 1.17 ]
Heterogeneity: Tau2 = 0.42; Chi2 = 9.75, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 0.77 (P = 0.44)
Total (95% CI) 137 133 100.0 % 0.17 [ -0.23, 0.57 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 12.63, df = 5 (P = 0.03); I2 =60%
Test for overall effect: Z = 0.83 (P = 0.41)
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Analysis 5.3. Comparison 5 Diuresis during study period (L), Outcome 3 Diuresis during study period
(stratified for type of surgery).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 5 Diuresis during study period (L)
Outcome: 3 Diuresis during study period (stratified for type of surgery)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiovascular surgery
Bruegger 2005 14 1.2 (0.55) 14 1.5 (1.33) 14.5 % -0.29 [ -1.03, 0.46 ]
Cross 1989 11 4.5 (0.5) 9 3.8 (0.25) 9.8 % 1.64 [ 0.59, 2.69 ]
Jarvela 2001 36 3.36 (1.04) 36 2.94 (0.85) 20.6 % 0.44 [ -0.03, 0.91 ]
Shackford 1983 30 1.6 (0.8) 28 1.8 (1.6) 19.4 % -0.16 [ -0.67, 0.36 ]
Shackford 1987 26 0.7 (0.7) 26 1.1 (5.8) 18.8 % -0.10 [ -0.64, 0.45 ]
Subtotal (95% CI) 117 113 83.0 % 0.21 [ -0.29, 0.70 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 12.70, df = 4 (P = 0.01); I2 =69%
Test for overall effect: Z = 0.82 (P = 0.41)
2 Non cardiovascular surgery
Jarvela 2000 20 0.5 (0.28) 20 0.43 (0.27) 17.0 % 0.25 [ -0.37, 0.87 ]
Subtotal (95% CI) 20 20 17.0 % 0.25 [ -0.37, 0.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI) 137 133 100.0 % 0.20 [ -0.20, 0.61 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 12.79, df = 5 (P = 0.03); I2 =61%
Test for overall effect: Z = 0.98 (P = 0.32)
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Analysis 5.4. Comparison 5 Diuresis during study period (L), Outcome 4 Diuresis during study period
(stratified for volume of crystalloid infused).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 5 Diuresis during study period (L)
Outcome: 4 Diuresis during study period (stratified for volume of crystalloid infused)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 2000 mL
Bruegger 2005 14 1.2 (0.55) 14 1.5 (1.33) 14.4 % -0.29 [ -1.03, 0.46 ]
Jarvela 2000 20 0.45 (0.28) 20 0.43 (0.27) 17.0 % 0.07 [ -0.55, 0.69 ]
Subtotal (95% CI) 34 34 31.4 % -0.07 [ -0.55, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
2 2000 - 5000 mL
Cross 1989 11 4.5 (0.5) 9 3.8 (0.25) 9.6 % 1.64 [ 0.59, 2.69 ]
Jarvela 2001 36 3.34 (1.04) 36 2.94 (0.85) 20.7 % 0.42 [ -0.05, 0.88 ]
Subtotal (95% CI) 47 45 30.3 % 0.94 [ -0.25, 2.12 ]
Heterogeneity: Tau2 = 0.58; Chi2 = 4.38, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 1.55 (P = 0.12)
3 > 5000 mL
Shackford 1983 30 1.6 (0.8) 28 1.8 (1.6) 19.5 % -0.16 [ -0.67, 0.36 ]
Shackford 1987 26 0.7 (0.7) 26 1.1 (5.8) 18.8 % -0.10 [ -0.64, 0.45 ]
Subtotal (95% CI) 56 54 38.3 % -0.13 [ -0.50, 0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI) 137 133 100.0 % 0.17 [ -0.23, 0.57 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 12.53, df = 5 (P = 0.03); I2 =60%
Test for overall effect: Z = 0.82 (P = 0.41)
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Analysis 5.5. Comparison 5 Diuresis during study period (L), Outcome 5 Diuresis during study period
(sensitivity analysis by study quality).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 5 Diuresis during study period (L)
Outcome: 5 Diuresis during study period (sensitivity analysis by study quality)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Study grade = A
Jarvela 2000 20 0.45 (0.28) 20 0.43 (0.27) 17.0 % 0.07 [ -0.55, 0.69 ]
Jarvela 2001 36 3.34 (1.04) 36 2.94 (0.85) 20.7 % 0.42 [ -0.05, 0.88 ]
Subtotal (95% CI) 56 56 37.7 % 0.29 [ -0.08, 0.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
2 Study grade = B
Bruegger 2005 14 1.2 (0.55) 14 1.5 (1.33) 14.4 % -0.29 [ -1.03, 0.46 ]
Cross 1989 11 4.5 (0.5) 9 3.8 (0.25) 9.6 % 1.64 [ 0.59, 2.69 ]
Shackford 1987 26 0.7 (0.7) 26 1.1 (5.8) 18.8 % -0.10 [ -0.64, 0.45 ]
Subtotal (95% CI) 51 49 42.8 % 0.33 [ -0.64, 1.30 ]
Heterogeneity: Tau2 = 0.58; Chi2 = 9.84, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 0.67 (P = 0.50)
3 Study grade = D
Shackford 1983 30 1.6 (0.8) 28 1.8 (1.6) 19.5 % -0.16 [ -0.67, 0.36 ]
Subtotal (95% CI) 30 28 19.5 % -0.16 [ -0.67, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 137 133 100.0 % 0.17 [ -0.23, 0.57 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 12.53, df = 5 (P = 0.03); I2 =60%
Test for overall effect: Z = 0.82 (P = 0.41)
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Analysis 6.1. Comparison 6 Peak serum sodium (meq/L), Outcome 1 Peak serum sodium (stratified by type
of surgery).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 6 Peak serum sodium (meq/L)
Outcome: 1 Peak serum sodium (stratified by type of surgery)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiovascular surgery
Bruegger 2005 14 159 (3) 14 143 (1) 4.6 % 6.95 [ 4.85, 9.04 ]
Cross 1989 11 145.4 (1.4) 9 139 (1) 4.9 % 4.95 [ 3.02, 6.88 ]
Jarvela 2001 36 150 (3) 36 140 (2) 7.7 % 3.88 [ 3.08, 4.68 ]
Shackford 1983 30 151 (7.6) 28 139 (7.6) 8.1 % 1.56 [ 0.96, 2.15 ]
Shackford 1987 26 157 (7.2) 26 140 (7.2) 7.8 % 2.33 [ 1.61, 3.04 ]
Younes 1988 18 147 (9) 13 137 (5) 7.7 % 1.28 [ 0.49, 2.07 ]
Subtotal (95% CI) 135 126 40.8 % 3.20 [ 1.98, 4.42 ]
Heterogeneity: Tau2 = 1.96; Chi2 = 53.42, df = 5 (P<0.00001); I2 =91%
Test for overall effect: Z = 5.14 (P < 0.00001)
2 Transurethral resection of the prostate
Baraka 1994 17 138.5 (5) 16 137 (3) 7.9 % 0.35 [ -0.34, 1.04 ]
Kato 1996 20 145 (4.4) 20 139.9 (2.4) 7.9 % 1.41 [ 0.71, 2.11 ]
Kimura 1994 7 142 (1) 7 137 (3) 6.2 % 2.09 [ 0.70, 3.48 ]
Subtotal (95% CI) 44 43 22.0 % 1.17 [ 0.22, 2.11 ]
Heterogeneity: Tau2 = 0.48; Chi2 = 7.09, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 2.42 (P = 0.015)
3 Other surgery
Ishikawa 1996 8 144.1 (3.4) 7 139 (3.5) 6.8 % 1.39 [ 0.22, 2.56 ]
Jarvela 2000 20 145 (2) 20 140 (2) 7.6 % 2.45 [ 1.61, 3.29 ]
Kolsen-Petersen 2004 19 150 (3) 20 141 (3) 7.4 % 2.94 [ 2.01, 3.87 ]
Veroli 1992 10 143.7 (1.7) 20 139.95 (1.8) 7.3 % 2.06 [ 1.12, 3.01 ]
Wang 1997 30 142 (5) 30 139 (3) 8.2 % 0.72 [ 0.19, 1.24 ]
Subtotal (95% CI) 87 97 37.2 % 1.89 [ 0.97, 2.81 ]
Heterogeneity: Tau2 = 0.89; Chi2 = 23.84, df = 4 (P = 0.00009); I2 =83%
Test for overall effect: Z = 4.03 (P = 0.000055)
Total (95% CI) 266 266 100.0 % 2.24 [ 1.59, 2.89 ]
Heterogeneity: Tau2 = 1.28; Chi2 = 107.32, df = 13 (P<0.00001); I2 =88%
Test for overall effect: Z = 6.72 (P < 0.00001)
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Analysis 6.2. Comparison 6 Peak serum sodium (meq/L), Outcome 2 Peak serum sodium (stratified by dose
of HS).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 6 Peak serum sodium (meq/L)
Outcome: 2 Peak serum sodium (stratified by dose of HS)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 7.1 mL 3% HS/kg
Baraka 1994 17 138.5 (5) 16 137 (3) 7.9 % 0.35 [ -0.34, 1.04 ]
Ishikawa 1996 8 144.1 (3.4) 7 139 (3.5) 6.8 % 1.39 [ 0.22, 2.56 ]
Kato 1996 20 145 (4.4) 20 139.9 (2.4) 7.9 % 1.41 [ 0.71, 2.11 ]
Veroli 1992 10 143.7 (1.7) 20 139.95 (1.8) 7.3 % 2.06 [ 1.12, 3.01 ]
Wang 1997 30 142 (5) 30 139 (3) 8.2 % 0.72 [ 0.19, 1.24 ]
Subtotal (95% CI) 85 93 38.1 % 1.11 [ 0.54, 1.68 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 11.14, df = 4 (P = 0.02); I2 =64%
Test for overall effect: Z = 3.83 (P = 0.00013)
2 7.1 - 10 mL 3% HS/kg
Bruegger 2005 14 159 (3) 14 143 (1) 4.6 % 6.95 [ 4.85, 9.04 ]
Jarvela 2000 20 145 (2) 20 140 (2) 7.6 % 2.45 [ 1.61, 3.29 ]
Jarvela 2001 36 150 (3) 36 140 (2) 7.7 % 3.88 [ 3.08, 4.68 ]
Kolsen-Petersen 2004 19 150 (3) 20 141 (3) 7.4 % 2.94 [ 2.01, 3.87 ]
Younes 1988 18 147 (9) 13 137 (5) 7.7 % 1.28 [ 0.49, 2.07 ]
Subtotal (95% CI) 107 103 34.8 % 3.26 [ 1.96, 4.57 ]
Heterogeneity: Tau2 = 1.88; Chi2 = 36.95, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 4.91 (P < 0.00001)
3 > 10 mL 3% HS/kg
Cross 1989 11 145.4 (1.4) 9 139 (1) 4.9 % 4.95 [ 3.02, 6.88 ]
Kimura 1994 7 142 (1) 7 137 (3) 6.2 % 2.09 [ 0.70, 3.48 ]
Shackford 1983 30 151 (7.6) 28 139 (7.6) 8.1 % 1.56 [ 0.96, 2.15 ]
Shackford 1987 26 157 (7.2) 26 140 (7.2) 7.8 % 2.33 [ 1.61, 3.04 ]
Subtotal (95% CI) 74 70 27.1 % 2.43 [ 1.44, 3.41 ]
Heterogeneity: Tau2 = 0.69; Chi2 = 11.94, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 4.83 (P < 0.00001)
Total (95% CI) 266 266 100.0 % 2.24 [ 1.59, 2.89 ]
Heterogeneity: Tau2 = 1.28; Chi2 = 107.32, df = 13 (P<0.00001); I2 =88%
Test for overall effect: Z = 6.72 (P < 0.00001)
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Analysis 6.3. Comparison 6 Peak serum sodium (meq/L), Outcome 3 Peak serum sodium (stratified by
volume given in control group).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 6 Peak serum sodium (meq/L)
Outcome: 3 Peak serum sodium (stratified by volume given in control group)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 2000 mL/kg
Jarvela 2000 20 145 (2) 20 140 (2) 11.9 % 2.45 [ 1.61, 3.29 ]
Kato 1996 20 145 (4.4) 20 139.9 (2.4) 12.4 % 1.41 [ 0.71, 2.11 ]
Veroli 1992 10 143.7 (1.7) 20 139.95 (1.8) 11.5 % 2.06 [ 1.12, 3.01 ]
Younes 1988 18 147 (9) 13 137 (5) 12.1 % 1.28 [ 0.49, 2.07 ]
Subtotal (95% CI) 68 73 48.0 % 1.76 [ 1.22, 2.31 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 5.35, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 6.38 (P < 0.00001)
2 2000 - 5000 mL
Bruegger 2005 14 159 (3) 14 143 (1) 7.0 % 6.95 [ 4.85, 9.04 ]
Cross 1989 11 145.4 (1.4) 9 139 (1) 7.6 % 4.95 [ 3.02, 6.88 ]
Jarvela 2001 36 150 (3) 36 140 (2) 12.1 % 3.88 [ 3.08, 4.68 ]
Subtotal (95% CI) 61 59 26.8 % 5.06 [ 3.28, 6.84 ]
Heterogeneity: Tau2 = 1.79; Chi2 = 7.59, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 5.58 (P < 0.00001)
3 > 5000 mL
Shackford 1983 30 151 (7.6) 28 139 (7.6) 12.8 % 1.56 [ 0.96, 2.15 ]
Shackford 1987 26 157 (7.2) 26 140 (7.2) 12.4 % 2.33 [ 1.61, 3.04 ]
Subtotal (95% CI) 56 54 25.2 % 1.91 [ 1.16, 2.67 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 2.62, df = 1 (P = 0.11); I2 =62%
Test for overall effect: Z = 5.00 (P < 0.00001)
Total (95% CI) 185 186 100.0 % 2.69 [ 1.89, 3.48 ]
Heterogeneity: Tau2 = 1.20; Chi2 = 59.62, df = 8 (P<0.00001); I2 =87%
Test for overall effect: Z = 6.60 (P < 0.00001)
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Analysis 6.4. Comparison 6 Peak serum sodium (meq/L), Outcome 4 Peak serum sodium (sensitivity
analysis by study quality).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 6 Peak serum sodium (meq/L)
Outcome: 4 Peak serum sodium (sensitivity analysis by study quality)
Study or subgroup Hypertonic saline Isotonic solution Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Study grade = A
Jarvela 2000 20 145 (2) 20 140 (2) 7.8 % 5.00 [ 3.76, 6.24 ]
Jarvela 2001 36 150 (3) 36 140 (2) 7.8 % 10.00 [ 8.82, 11.18 ]
Subtotal (95% CI) 56 56 15.5 % 7.50 [ 2.60, 12.40 ]
Heterogeneity: Tau2 = 12.12; Chi2 = 32.85, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 3.00 (P = 0.0027)
2 Study grade = B
Baraka 1994 17 138.5 (5) 16 137 (3) 7.0 % 1.50 [ -1.29, 4.29 ]
Bruegger 2005 14 159 (3) 14 143 (1) 7.6 % 16.00 [ 14.34, 17.66 ]
Cross 1989 11 145.4 (1.4) 9 139 (1) 7.8 % 6.40 [ 5.35, 7.45 ]
Ishikawa 1996 8 144.1 (3.4) 7 139 (3.5) 6.6 % 5.10 [ 1.60, 8.60 ]
Kato 1996 20 145 (4.4) 20 139.9 (2.4) 7.3 % 5.10 [ 2.90, 7.30 ]
Kimura 1994 7 142 (1) 7 137 (3) 7.3 % 5.00 [ 2.66, 7.34 ]
Kolsen-Petersen 2004 19 150 (3) 20 141 (3) 7.5 % 9.00 [ 7.12, 10.88 ]
Shackford 1987 26 157 (7.2) 26 140 (7.2) 6.3 % 17.00 [ 13.09, 20.91 ]
Veroli 1992 10 143.7 (1.7) 20 139.95 (1.8) 7.7 % 3.75 [ 2.43, 5.07 ]
Wang 1997 30 142 (5) 30 139 (3) 7.4 % 3.00 [ 0.91, 5.09 ]
Younes 1988 18 147 (9) 13 137 (5) 5.6 % 10.00 [ 5.03, 14.97 ]
Subtotal (95% CI) 180 182 78.2 % 7.33 [ 4.59, 10.08 ]
Heterogeneity: Tau2 = 19.76; Chi2 = 204.53, df = 10 (P<0.00001); I2 =95%
Test for overall effect: Z = 5.23 (P < 0.00001)
3 Study grade = D
Shackford 1983 30 151 (7.6) 28 139 (7.6) 6.3 % 12.00 [ 8.09, 15.91 ]
Subtotal (95% CI) 30 28 6.3 % 12.00 [ 8.09, 15.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.01 (P < 0.00001)
Total (95% CI) 266 266 100.0 % 7.64 [ 5.47, 9.80 ]
Heterogeneity: Tau2 = 15.32; Chi2 = 245.24, df = 13 (P<0.00001); I2 =95%
Test for overall effect: Z = 6.92 (P < 0.00001)
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Analysis 7.1. Comparison 7 Final serum sodium (meq/L), Outcome 1 Final serum sodium (all studies).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 7 Final serum sodium (meq/L)
Outcome: 1 Final serum sodium (all studies)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bruegger 2005 6 143 (5.3) 6 140 (4) 7.4 % 0.59 [ -0.58, 1.76 ]
Cross 1989 11 144 (2) 9 139.5 (1) 6.8 % 2.64 [ 1.37, 3.91 ]
Jarvela 2000 20 145 (2) 20 140 (2) 9.5 % 2.45 [ 1.61, 3.29 ]
Jarvela 2001 20 141 (1) 20 139 (1) 10.0 % 1.96 [ 1.19, 2.73 ]
Kato 1996 20 140.6 (2.6) 20 138.6 (2.4) 10.8 % 0.78 [ 0.14, 1.43 ]
Kolsen-Petersen 2004 19 139 (2) 20 138 (1) 10.8 % 0.62 [ -0.02, 1.27 ]
Shackford 1983 30 146 (7.6) 28 136 (15.2) 11.5 % 0.83 [ 0.29, 1.37 ]
Shackford 1987 26 145 (7.2) 26 139 (7.2) 11.3 % 0.82 [ 0.25, 1.39 ]
Wang 1997 30 142 (5) 30 138 (3) 11.5 % 0.96 [ 0.42, 1.49 ]
Younes 1988 18 136 (7) 13 138 (6) 10.3 % -0.29 [ -1.01, 0.42 ]
Total (95% CI) 200 192 100.0 % 1.07 [ 0.60, 1.54 ]
Heterogeneity: Tau2 = 0.42; Chi2 = 39.29, df = 9 (P = 0.00001); I2 =77%
Test for overall effect: Z = 4.48 (P < 0.00001)
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Analysis 7.2. Comparison 7 Final serum sodium (meq/L), Outcome 2 Final serum sodium (stratified by dose
of HS given).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 7 Final serum sodium (meq/L)
Outcome: 2 Final serum sodium (stratified by dose of HS given)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 7.1 mL 3% HS/kg
Kato 1996 20 140.6 (2.6) 20 138.6 (2.4) 10.8 % 0.78 [ 0.14, 1.43 ]
Wang 1997 30 142 (5) 30 138 (3) 11.5 % 0.96 [ 0.42, 1.49 ]
Subtotal (95% CI) 50 50 22.4 % 0.89 [ 0.47, 1.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 4.21 (P = 0.000025)
2 7.1 - 10 mL 3% HS/kg
Bruegger 2005 6 143 (5.3) 6 140 (4) 7.4 % 0.59 [ -0.58, 1.76 ]
Jarvela 2000 20 145 (2) 20 140 (2) 9.5 % 2.45 [ 1.61, 3.29 ]
Jarvela 2001 20 141 (1) 20 139 (1) 10.0 % 1.96 [ 1.19, 2.73 ]
Kolsen-Petersen 2004 19 139 (2) 20 138 (1) 10.8 % 0.62 [ -0.02, 1.27 ]
Younes 1988 18 136 (7) 13 138 (6) 10.3 % -0.29 [ -1.01, 0.42 ]
Subtotal (95% CI) 83 79 48.0 % 1.07 [ 0.06, 2.07 ]
Heterogeneity: Tau2 = 1.13; Chi2 = 31.78, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.08 (P = 0.038)
3 > 10 mL 3% HS/kg
Cross 1989 11 144 (2) 9 139.5 (1) 6.8 % 2.64 [ 1.37, 3.91 ]
Shackford 1983 30 146 (7.6) 28 136 (15.2) 11.5 % 0.83 [ 0.29, 1.37 ]
Shackford 1987 26 145 (7.2) 26 139 (7.2) 11.3 % 0.82 [ 0.25, 1.39 ]
Subtotal (95% CI) 67 63 29.7 % 1.21 [ 0.43, 2.00 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 7.17, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 3.04 (P = 0.0024)
Total (95% CI) 200 192 100.0 % 1.07 [ 0.60, 1.54 ]
Heterogeneity: Tau2 = 0.42; Chi2 = 39.29, df = 9 (P = 0.00001); I2 =77%
Test for overall effect: Z = 4.48 (P < 0.00001)
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Analysis 7.3. Comparison 7 Final serum sodium (meq/L), Outcome 3 Final serum sodium (stratified by
volume given in control group).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 7 Final serum sodium (meq/L)
Outcome: 3 Final serum sodium (stratified by volume given in control group)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 < 2000 mL
Jarvela 2000 20 145 (2) 20 140 (2) 12.3 % 2.45 [ 1.61, 3.29 ]
Kato 1996 20 140.6 (2.6) 20 138.6 (2.4) 13.6 % 0.78 [ 0.14, 1.43 ]
Younes 1988 18 136 (7) 13 138 (6) 13.1 % -0.29 [ -1.01, 0.42 ]
Subtotal (95% CI) 58 53 39.1 % 0.96 [ -0.49, 2.42 ]
Heterogeneity: Tau2 = 1.51; Chi2 = 23.78, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 1.30 (P = 0.19)
2 2000 - 5000 mL
Bruegger 2005 6 143 (5.3) 6 140 (4) 10.2 % 0.59 [ -0.58, 1.76 ]
Cross 1989 11 144 (2) 9 139.5 (1) 9.6 % 2.64 [ 1.37, 3.91 ]
Jarvela 2001 20 141 (1) 20 139 (1) 12.8 % 1.96 [ 1.19, 2.73 ]
Subtotal (95% CI) 37 35 32.6 % 1.73 [ 0.68, 2.78 ]
Heterogeneity: Tau2 = 0.57; Chi2 = 5.96, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 3.22 (P = 0.0013)
3 > 5000 mL
Shackford 1983 30 146 (7.6) 28 136 (15.2) 14.3 % 0.83 [ 0.29, 1.37 ]
Shackford 1987 26 145 (7.2) 26 139 (7.2) 14.1 % 0.82 [ 0.25, 1.39 ]
Subtotal (95% CI) 56 54 28.3 % 0.83 [ 0.43, 1.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 4.14 (P = 0.000034)
Total (95% CI) 151 142 100.0 % 1.17 [ 0.55, 1.79 ]
Heterogeneity: Tau2 = 0.62; Chi2 = 38.07, df = 7 (P<0.00001); I2 =82%
Test for overall effect: Z = 3.70 (P = 0.00022)
-4 -2 0 2 4
Hypertonic saline Isotonic solution
54Hypertonic saline for peri-operative fluid management (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.4. Comparison 7 Final serum sodium (meq/L), Outcome 4 Final serum sodium (stratified by type
of surgery).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 7 Final serum sodium (meq/L)
Outcome: 4 Final serum sodium (stratified by type of surgery)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiovascular surgery
Bruegger 2005 6 143 (5.3) 6 140 (4) 7.4 % 0.59 [ -0.58, 1.76 ]
Cross 1989 11 144 (2) 9 139.5 (1) 6.8 % 2.64 [ 1.37, 3.91 ]
Jarvela 2001 20 141 (1) 20 139 (1) 10.0 % 1.96 [ 1.19, 2.73 ]
Shackford 1983 30 146 (7.6) 28 136 (15.2) 11.5 % 0.83 [ 0.29, 1.37 ]
Shackford 1987 26 145 (7.2) 26 139 (7.2) 11.3 % 0.82 [ 0.25, 1.39 ]
Subtotal (95% CI) 93 89 47.0 % 1.28 [ 0.65, 1.91 ]
Heterogeneity: Tau2 = 0.34; Chi2 = 13.09, df = 4 (P = 0.01); I2 =69%
Test for overall effect: Z = 3.96 (P = 0.000075)
2 Transurethral resection of prostate
Kato 1996 20 140.6 (2.6) 20 138.6 (2.4) 10.8 % 0.78 [ 0.14, 1.43 ]
Subtotal (95% CI) 20 20 10.8 % 0.78 [ 0.14, 1.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.38 (P = 0.017)
3 Other surgery
Jarvela 2000 20 145 (2) 20 140 (2) 9.5 % 2.45 [ 1.61, 3.29 ]
Kolsen-Petersen 2004 19 139 (2) 20 138 (1) 10.8 % 0.62 [ -0.02, 1.27 ]
Wang 1997 30 142 (5) 30 138 (3) 11.5 % 0.96 [ 0.42, 1.49 ]
Younes 1988 18 136 (7) 13 138 (6) 10.3 % -0.29 [ -1.01, 0.42 ]
Subtotal (95% CI) 87 83 42.1 % 0.91 [ -0.04, 1.87 ]
Heterogeneity: Tau2 = 0.83; Chi2 = 24.37, df = 3 (P = 0.00002); I2 =88%
Test for overall effect: Z = 1.87 (P = 0.061)
Total (95% CI) 200 192 100.0 % 1.07 [ 0.60, 1.54 ]
Heterogeneity: Tau2 = 0.42; Chi2 = 39.29, df = 9 (P = 0.00001); I2 =77%
Test for overall effect: Z = 4.48 (P < 0.00001)
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Analysis 7.5. Comparison 7 Final serum sodium (meq/L), Outcome 5 Final serum sodium (sensitivity
analysis by study quality).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 7 Final serum sodium (meq/L)
Outcome: 5 Final serum sodium (sensitivity analysis by study quality)
Study or subgroup Hypertonic saline Isotonic solution Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Study grade = A
Jarvela 2000 20 145 (2) 20 140 (2) 13.8 % 5.00 [ 3.76, 6.24 ]
Jarvela 2001 20 141 (1) 20 139 (1) 15.3 % 2.00 [ 1.38, 2.62 ]
Subtotal (95% CI) 40 40 29.2 % 3.45 [ 0.51, 6.39 ]
Heterogeneity: Tau2 = 4.25; Chi2 = 18.00, df = 1 (P = 0.00002); I2 =94%
Test for overall effect: Z = 2.30 (P = 0.021)
2 Study grade = B
Bruegger 2005 6 143 (5.3) 6 140 (4) 4.2 % 3.00 [ -2.31, 8.31 ]
Cross 1989 11 144 (2) 9 139.5 (1) 13.5 % 4.50 [ 3.15, 5.85 ]
Kato 1996 20 140.6 (2.6) 20 138.6 (2.4) 12.9 % 2.00 [ 0.45, 3.55 ]
Kolsen-Petersen 2004 19 139 (2) 20 138 (1) 14.5 % 1.00 [ 0.00, 2.00 ]
Shackford 1987 26 145 (7.2) 26 139 (7.2) 6.3 % 6.00 [ 2.09, 9.91 ]
Wang 1997 30 142 (5) 30 138 (3) 11.1 % 4.00 [ 1.91, 6.09 ]
Younes 1988 18 136 (7) 13 138 (6) 5.1 % -2.00 [ -6.59, 2.59 ]
Subtotal (95% CI) 130 124 67.6 % 2.74 [ 1.11, 4.38 ]
Heterogeneity: Tau2 = 3.11; Chi2 = 26.15, df = 6 (P = 0.00021); I2 =77%
Test for overall effect: Z = 3.28 (P = 0.0010)
3 Study grade = D
Shackford 1983 30 146 (7.6) 28 136 (15.2) 3.3 % 10.00 [ 3.75, 16.25 ]
Subtotal (95% CI) 30 28 3.3 % 10.00 [ 3.75, 16.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0017)
Total (95% CI) 200 192 100.0 % 3.18 [ 1.91, 4.44 ]
Heterogeneity: Tau2 = 2.61; Chi2 = 49.84, df = 9 (P<0.00001); I2 =82%
Test for overall effect: Z = 4.92 (P < 0.00001)
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Analysis 12.1. Comparison 12 Other outcomes of interest, Outcome 1 Maximum intraoperative serum
osmolarity (mOsm/kg H2O).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 12 Other outcomes of interest
Outcome: 1 Maximum intraoperative serum osmolarity (mOsm/kg H2O)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ishikawa 1996 8 295.8 (4.4) 7 281.5 (10.2) 10.8 % 1.76 [ 0.51, 3.01 ]
Jarvela 2000 20 302 (5) 20 292 (3) 12.0 % 2.38 [ 1.55, 3.20 ]
Jarvela 2001 20 313 (6) 20 290 (4) 11.0 % 4.42 [ 3.23, 5.61 ]
Kato 1996 20 298.2 (6.1) 20 284.3 (3.5) 11.8 % 2.74 [ 1.85, 3.62 ]
Kimura 1994 7 296 (4) 7 287 (7) 10.9 % 1.48 [ 0.25, 2.71 ]
Kolsen-Petersen 2004 19 302 (2) 20 285 (0.5) 6.4 % 11.56 [ 8.78, 14.34 ]
Shackford 1983 30 301 (15.2) 28 284 (7.6) 12.5 % 1.38 [ 0.80, 1.96 ]
Shackford 1987 26 309 (14.4) 26 284 (7.2) 12.3 % 2.16 [ 1.47, 2.86 ]
Younes 1988 18 327 (11) 13 320 (8) 12.2 % 0.69 [ -0.05, 1.43 ]
Total (95% CI) 168 161 100.0 % 2.72 [ 1.73, 3.71 ]
Heterogeneity: Tau2 = 1.95; Chi2 = 82.38, df = 8 (P<0.00001); I2 =90%
Test for overall effect: Z = 5.38 (P < 0.00001)
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Analysis 12.2. Comparison 12 Other outcomes of interest, Outcome 2 Maximum intraoperative pulmonary
artery wedge pressure (mm Hg).
Review: Hypertonic saline for peri-operative fluid management
Comparison: 12 Other outcomes of interest
Outcome: 2 Maximum intraoperative pulmonary artery wedge pressure (mm Hg)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Jarvela 2001 20 9.1 (3.5) 20 8.4 (4.5) 26.6 % 0.17 [ -0.45, 0.79 ]
Shackford 1983 30 10 (7.6) 28 11 (7.6) 38.6 % -0.13 [ -0.65, 0.39 ]
Shackford 1987 26 11 (7.2) 26 11 (7.2) 34.7 % 0.0 [ -0.54, 0.54 ]
Total (95% CI) 76 74 100.0 % 0.00 [ -0.33, 0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
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Review: Hypertonic saline for peri-operative fluid management
Comparison: 12 Other outcomes of interest
Outcome: 3 Maximum intraoperative cardiac index (L/min/M2)
Study or subgroup Hypertonic saline Isotonic solution Std. Mean Difference Weight Std. Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cross 1989 11 3.1 (0.3) 9 2.65 (0.3) 12.6 % 1.44 [ 0.43, 2.45 ]
Jarvela 2000 20 3.19 (0.5) 20 3.02 (0.65) 20.9 % 0.29 [ -0.34, 0.91 ]
Jarvela 2001 20 3.2 (1) 20 2.3 (0.5) 19.6 % 1.12 [ 0.44, 1.79 ]
Shackford 1983 30 3.1 (0.8) 28 3 (0.8) 23.9 % 0.12 [ -0.39, 0.64 ]
Shackford 1987 26 3.7 (1.2) 26 3.4 (1.2) 23.0 % 0.25 [ -0.30, 0.79 ]
Total (95% CI) 107 103 100.0 % 0.55 [ 0.10, 1.00 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 9.77, df = 4 (P = 0.04); I2 =59%
Test for overall effect: Z = 2.38 (P = 0.017)
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A P P E N D I C E S
Appendix 1. MEDLINE (1966 to April 2007)
#1 explode saline solution, hypertonic/all subheadings
#2 explode hypertonic solutions/all subheadings
#3 (hypertonic NaCl) or (hypertonic saline) or (hypertonic solution*)
#4 Ringer’s solution/ all subheadings
#5 #1 or #2 or #3 or #4
#6 #5 not (explode glucose solution, hypertonic / all subheadings)
#7 #6 not colloid*
#8 explode surgical procedures, operative/all subheadings
#9 explode specialties, surgical/ all subheadings
#10 explode surgery/ all subheadings
#11 (surg* near procedur*) or surger* or operat*
#12 #8 or #9 or #10 or #11
#13 #7 and #12
#14 RANDOMIZED-CONTROLLED-TRIAL in PT
#15 CONTROLLED-CLINICAL-TRIAL in PT
#16 explode RANDOMIZED-CONTROLLED-TRIALS/all subheadings
#17 explode RANDOM-ALLOCATION/all subheadings
#18 explode DOUBLE-BLIND-METHOD/all subheadings
#19 explode SINGLE-BLIND-METHOD/all subheadings
#20 #14 or #15 or #16 or #17 or #18 or #19
#21 (TG=ANIMALS) not ((TG=HUMAN) and (TG=ANIMALS))
#22 #20 not #21
#23 CLINICAL-TRIAL in PT
#24 explode CLINICAL-TRIALS / all subheadings
#25 (clin* near trial*) in TI
#26 (clin* near trial*) in AB
#27 (singl* or doubl* or trebl* or tripl*) near (blind* or mask*)
#28 (#27 in TI) or (#27 in AB)
#29 explode PLACEBOS/ all subheadings
#30 placebo* in TI
#31 placebo* in AB
#32 random* in TI
#33 random* in AB
#34 explode RESEARCH-DESIGN/all subheadings
#35 #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33
or #34
#36 (TG=ANIMALS) not ((TG=HUMAN) and (TG=ANIMALS))
#37 #35 not #36
#38 #37 not #22
#39 TG=COMPARATIVE-STUDY
#40 explode EVALUATION-STUDIES/all subheadings
#41 explode FOLLOW-UP-STUDIES/all subheadings
#42 explode PROSPECTIVE-STUDIES/all subheadings
#43 control* or prospectiv* or volunteer*
#44 (#43 in TI) or (#43 in AB)
#45 #39 or #40 or #41 or #42 or #43 or #44
#46 (TG=ANIMALS) not ((TG=HUMAN) and (TG=ANIMALS))
#47 #45 not #46
#48 #47 not (#22 or #38)
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#49 #22 or #38 or #48
#50 #13 and #49
Appendix 2. EMBASE (1980 to 2007 week 18)
#1 saline solution
#2 explode “hypertonic-solution” / all SUBHEADINGS in DEM,DER,DRM,DRR
#3 (hypertonic NaCl) or (hypertonic saline) or (hypertonic solution*)
#4 “Ringer-solution” / all SUBHEADINGS in DEM,DER,DRM,DRR
#5 sodium chloride in TI, AB
#6 #1 or #2 or #3 or #4 or #5
#7 #6 not (glucose or fructose)
#8 explode surgery/ all subheadings
#9 (surg* near procedur*) or surger* or operat*
#10 “surgical-technique” / all SUBHEADINGS in DEM,DER,DRM,DRR
#11 #8 or #9 or #10
#12 #7 and #11
#13 explode “randomized-controlled-trial” / all SUBHEADINGS in DEM,DER,DRM,DRR
#14 (randomi?ed controlled trial*) in TI, AB
#15 random*
#16 explode “randomization-” / all SUBHEADINGS in DEM,DER,DRM,DRR
#17 randomi?ation
#18 explode “clinical-trial” / all SUBHEADINGS in DEM,DER,DRM,DRR
#19 clinical near trial*
#20 explode multicenter-study / all subheadings
#21 multi?cent*
#22 explode phase-4-clinical-trial / all subheadings or explode double-blind-procedure / all subheadings or explode single-blind-
procedure / all subheadings
#23 (RANDOM* or CROSS?OVER* or FACTORIAL* or PLACEBO* or VOLUNTEER*) in TI, AB, TW
#24 ((SINGL* or DOUBL* or TREBL* or TRIPL*) near (BLIND* or MASK*)) in TI,AB
#25 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24
#26 (human) in DER
#27 (animal or nonhuman) in DER
#28 #26 and #27
#29 #27 not #28
#30 #25 not #29
#31 #12 and #30
Appendix 3. CINAHL (1982 to April week 1, 2007)
#1 explode “Saline-Solution-Hypertonic” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#2 explode “Hypertonic-Solutions” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#3 (hypertonic NaCl) or (hypertonic saline) or (hypertonic solution*)
#4 explode “Lactated-Ringer’s-Solution” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#5 explode “Sodium-Chloride” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#6 #1 or #2 or #3 or #4 or #5
#7 #6 not (glucose or fructose)
#8 explode “Surgery-Operative” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#9 (surg* near procedur*) or (surg* and procedur*)or surger* or operat*
#10 #8 or #9
#11 #7 and #10
#12 Randomized Clinical Trial*
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#13 Controlled Clinical Trial*
#14 explode “Random-Assignment” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#15 “Double-Blind-Studies” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#16 “Single-Blind-Studies” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#17 explode “Clinical-Trials” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#18 (clin* near trial*) in TI
#19 (clin* near trial*) in AB
#20 (singl* or doubl* or trebl* or tripl*) near (blind* or mask*)
#21 (#20 in TI) or (#20 in AB)
#22 “Placebos-” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#23 placebo* in TI
#24 placebo* in AB
#25 random* in TI
#26 random* in AB
#27 “Study-Design” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#28 “Comparative-Studies” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#29 explode “Evaluation-Research” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#30 “Prospective-Studies” / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE
#31 control* or prospectiv* or volunteer*
#32 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29
or #30 or #31
#33 sheep or dog* or cat* or guinea?pig* or mouse or experimental animal*
#34 explode animals/ all topical subheadings / all age subheadings
#35 #33 or #34
#36 human*
#37 #35 not (#34 and #35)
#38 #32 not #37
#39 #11 and #38
Appendix 4. LILACS (1982 to April 2007)
“HYPERTONIC” or “HYPERTONIC SALINE SOLUTION/” or “HYPERTONIC SOLUTION, SALINE/” or “HYPERTONIC
SOLUTIONS/” or “RINGER” or “SODIUM CHLORIDE” or “SODIUM CHLORIDE SOLUTION, HYPERTONIC/” [Words]
and “SURGERY” or “SURGICAL” or “OPERATION” or “surg$” or “operat$” [Words]
Appendix 5. CENTRAL, (The Cochrane Library, 2007 Issue 1)
#1 MeSH descriptor Sodium Chloride explode all trees
#2 MeSH descriptor Saline Solution, Hypertonic explode all trees
#3 ( (hypertonic in All Text and NaCl in All Text) or (hypertonic in All Text and saline in All Text) or (hypertonic in All Text and
solution* in All Text) )
#4 (Ringer’s in All Text and solution in All Text)
#5 (#1 or #2 or #3 or #4)
#6 MeSH descriptor Glucose Solution, Hypertonic explode all trees
#7 (#5 and not #6)
#8 (#7 and not colloid* in All Text)
#9 MeSH descriptor surgical procedures, operative explode all trees
#10 MeSH descriptor Specialties, Surgical explode all trees
#11 MeSH descriptor Specialties, Dental explode all trees
#12 MeSH descriptor Surgery explode all trees
#13 (surg* in All Text near/6 procedur* in All Text)
#14 (surger* in All Text or operat* in All Text)
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#15 (#9 or #10 or #11 or #12 or #13 or #14)
#16 (#8 and #15)
5 not #36
#38 #37 not #22
#39 TG=COMPARATIVE-STUDY
#40 explode EVALUATION-STUDIES/all subheadings
#41 explode FOLLOW-UP-STUDIES/all subheadings
#42 explode PROSPECTIVE-STUDIES/all subheadings
#43 control* or prospectiv* or volunteer*
#44 (#43 in TI) or (#43 in AB)
#45 #39 or #40 or #41 or #42 or #43 or #44
#46 (TG=ANIMALS) not ((TG=HUMAN) and (TG=ANIMALS))
#47 #45 not #46
#48 #47 not (#22 or #38)
#49 #22 or #38 or #48
#50 #13 and #49
Appendix 6. Search update: April 2007 to August 2009
Search strategy for EMBASE (Ovid SP)
#1. exp sodium chloride/ or Ringer solution/
#2. exp hypertonic solution/
#3. (hypertonic adj3 (NaCl or saline or solution*)).mp.
#4. #1 or #2 or #3
#5. (glucose or fructose).mp.
#6. #4 not #5
#7. surgery/ or ((surg* adj3 procedur*) or surger* or operat*).ti,ab.
#8. (RANDOM* or CROSS?OVER* or FACTORIAL* or PLACEBO* or VOLUNTEER* or ((SINGL* or DOUBL* or TREBL*
or TRIPL*) adj3 (BLIND* or MASK*))).mp. not (animal not (human and animal)).sh.
#9. #6 and #7 and #8
Search strategy for MEDLINE (Ovid SP)
#1. saline solution, hypertonic/or hypertonic solutions/
#2. (hypertonic adj3 (NaCl or saline or solution*)).mp. or ringer.mp.
#3. #1 or #2
#4. exp glucose solution, hypertonic/or colloid*.mp.
#5. #3 not #4
#6. exp surgical procedures, operative/or exp specialties, surgical/ or exp surgery/
#7. ((surg* adj3 procedur*) or surger* or operat*).mp.
#8. #6 or #7
#9. #8 and #5
#10. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab.
or trial.ab. or groups.ab.) not (animals not (humans and animals)).sh.
#11. #9 and #10
Search strategy for CINAHL (EBASCOhost)
S1. (MM “Saline Solution, Hypertonic”) or (MM “Hypertonic Solutions”)
S2. (MH “Lactated Ringer’s Solution”)
S3. TX (hypertonic and (NaCl or saline or solution*)) or Ringer
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S4. (MH “Sodium Chloride”)
S5. S1 or S2 or S3 or S4
S6. TX glucose or fructose
S7. S5 not S6
S8. (MH “Surgery, Operative”)
S9. TX surger* or operat*
S10. S8 or S9
S11. S7 and S10
Search strategy for CENTRAL, The Cochrane Library
#1 MeSH descriptor Saline Solution, Hypertonic explode all trees
#2 MeSH descriptor Hypertonic Solutions explode all trees
#3 (hypertonic NaCl) or (hypertonic saline) or (hypertonic solution*)
#4 Ringer* near solution*
#5 Sodium Chloride
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 MeSH descriptor Glucose Solution, Hypertonic, this term only
#8 (#6 AND NOT #7)
#9 MeSH descriptor Surgical Procedures, Operative explode all trees
#10 MeSH descriptor Specialties, Surgical explode all trees
#11 MeSH descriptor Surgery explode all trees
#12 (surg* near procedur*) or surger* or operat*
#13 (#9 OR #10 OR #11 OR #12)
#14 (#8 AND #13)
H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 1, 2010
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the review: T. Znajda (TZ), K. Burns (KB), V. McAlister (VM)
Co-ordinating the review: VM
Undertaking manual searches: TZ, K.B, VM
Screening search results: TZ, KB, VM, BC
Organizing retrieval of papers: TZ, VM
Screening retrieved papers against inclusion criteria: TZ, KB, VM
Appraising quality of papers: TZ, KB, VM
Abstracting data from papers: TZ, KB, VM, BC
Writing to authors of papers for additional information: VM
Obtaining and screening data on unpublished studies: TZ, KB, VM
Data management for the review: TZ, KB, VM
Entering data into Review Manager (RevMan 5.0): VM, KB
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RevMan statistical data: VM, KB
Other statistical analysis not using RevMan: KB
Double entry of data: (data entered by person one: VM ; data entered by person two: KB)
Interpretation of data: TZ, KB, VM
Statistical analysis: TZ, KB, VM
Writing the review: VM
Securing funding for the review: Not applicable
Performing previous work that was the foundation of the present study: TZ, KB, VM, BC
Guarantor for the review (one author) VM
Persons responsible for reading and checking review before submission:TZ, KB, VM, BC
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